_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502936087,7/14/2014 17:10:53,,1322968643,7/14/2014 17:10:33,instagc,1,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],and,N/a,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 17:13:19,,1322969851,7/14/2014 17:13:10,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],hyperventilation,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 17:29:36,,1322979347,7/14/2014 17:29:21,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 17:32:52,,1322982220,7/14/2014 17:32:09,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],and,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 17:45:46,,1322994751,7/14/2014 17:44:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is separate,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 17:59:53,,1323001154,7/14/2014 17:58:49,vivatic,1,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],conditions overlap;,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 18:00:49,,1323001662,7/14/2014 18:00:32,instagc,1,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PANIC PANIC,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 18:16:20,,1323010128,7/14/2014 18:16:02,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[MANIFESTATION],[MANIFESTATION],PANIC ATTACKS and Panic Disorder,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 18:44:54,,1323022571,7/14/2014 18:44:34,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 18:46:19,,1323023313,7/14/2014 18:45:15,instagc,1,19686223,CAN,BC,Surrey,184.65.16.6,[SYMPTOM],[SYMPTOM],patients with hyperventilation syndrome have panic disorder.,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 18:46:32,,1323023419,7/14/2014 18:46:20,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],PANIC ATTACKS PANIC DISORDER,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 19:00:12,,1323031772,7/14/2014 19:00:00,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PANIC Panic,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 19:08:56,,1323036936,7/14/2014 19:08:37,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],and,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 19:11:32,,1323038313,7/14/2014 19:11:09,instagc,1,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],PANIC ATTACKS and Panic Disorder,N/A,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936087,7/14/2014 19:37:34,,1323054281,7/14/2014 19:34:47,instagc,1,19636746,USA,NY,Andover,192.182.216.225,[SYMPTOM],[SYMPTOM],PANIC DISORDER,na,64,166,76,180,-1,RO-has_definitional_manifestation,904519-FS1,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
502936088,7/14/2014 17:13:29,,1322969940,7/14/2014 17:13:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],are responsible,N/a,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:13:46,,1322970102,7/14/2014 17:13:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related disorders;,Na,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:45:55,,1322994828,7/14/2014 17:45:09,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]","as a result of Stenosis of the Aqueduct of Sylvius),",[CAUSES] [SIDE_EFFECT],177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:46:27,,1322995070,7/14/2014 17:45:49,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[NONE],[NONE],N/A,unrelated disorders,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:49:22,,1322996399,7/14/2014 17:48:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],four related L1 disorders;,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:52:54,,1322998105,7/14/2014 17:51:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are related,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 17:54:51,,1322998937,7/14/2014 17:54:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as a result,n/a,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:08:11,,1323006257,7/14/2014 18:08:05,prodege,1,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:20:23,,1323011831,7/14/2014 18:19:56,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Mutations are responsible for X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS MASA (MENTAL RETARDATION,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:35:51,,1323018378,7/14/2014 18:35:20,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,related disorders,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:41:33,,1323021021,7/14/2014 18:40:51,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[MANIFESTATION],[MANIFESTATION],Mutations in the L1CAM gene are responsible for four related L1 disorders;,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:48:20,,1323024376,7/14/2014 18:47:34,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],disorders; result,none,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 18:56:37,,1323029099,7/14/2014 18:56:17,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(MENTAL thumbs),N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 19:05:56,,1323035330,7/14/2014 19:05:33,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],as a result of,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936088,7/14/2014 19:09:47,,1323037369,7/14/2014 19:09:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],four related L1 disorders;,N/A,177,75,194,117,-1,RO-has_manifestation,906021-FS1,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
502936089,7/14/2014 17:13:48,,1322970103,7/14/2014 17:13:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DOPA,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 17:23:01,,1322974590,7/14/2014 17:22:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],were confirmed,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 17:38:53,,1322987914,7/14/2014 17:37:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[OTHER],[OTHER],evaluating,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 17:47:39,,1322995653,7/14/2014 17:46:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluating by,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 17:57:31,,1323000208,7/14/2014 17:57:22,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],monotherapy,n/a,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 17:58:47,,1323000719,7/14/2014 17:57:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Clinical efficacy confirmed,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 18:12:39,,1323008412,7/14/2014 18:12:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],L DOPA UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),n/a,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 18:26:02,,1323014038,7/14/2014 18:25:31,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],were confirmed evaluating by,N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 18:44:33,,1323022422,7/14/2014 18:41:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluating by,n/a,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 18:46:57,,1323023660,7/14/2014 18:46:34,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 18:56:15,,1323028876,7/14/2014 18:54:57,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],L DOPA confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),N/A,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 19:01:38,,1323032711,7/14/2014 18:59:09,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were confirmed,Na,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 19:04:28,,1323034537,7/14/2014 19:03:51,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],were confirmed evaluating by,N/a,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 19:43:43,,1323057463,7/14/2014 19:43:07,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],confirmed evaluating,na,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936089,7/14/2014 19:49:15,,1323060686,7/14/2014 19:48:56,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],evaluating by,n/a,111,75,158,81,1,RO-may_treat,908169-FS1,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA
502936090,7/14/2014 17:10:31,,1322968457,7/14/2014 17:10:16,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],tolerance in the,N/a,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:20:47,,1322973439,7/14/2014 17:20:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],develop.,Na,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:30:14,,1322979883,7/14/2014 17:29:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],induce,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:31:20,,1322980828,7/14/2014 17:30:59,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in the,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:46:48,,1322995262,7/14/2014 17:46:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],tolerance in the,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:48:27,,1322995975,7/14/2014 17:47:39,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],induce to develop.,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 17:51:09,,1322997215,7/14/2014 17:49:27,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[LOCATION],[LOCATION],in the,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 18:14:15,,1323009209,7/14/2014 18:13:39,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],Repeated exposures in SKIN so that URTICARIA fails to develop.,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:04:30,,1323034560,7/14/2014 19:03:03,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[LOCATION],[LOCATION],fails to develop.,Na,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:04:32,,1323034574,7/14/2014 19:03:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the SKIN,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:06:00,,1323035363,7/14/2014 19:05:15,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],induce,none,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:08:38,,1323036789,7/14/2014 19:08:00,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],SKIN so that URTICARIA develop.,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:11:55,,1323038479,7/14/2014 19:11:37,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[LOCATION],[LOCATION],so that,N/A,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:44:11,,1323057744,7/14/2014 19:43:45,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CONTRAINDICATES],[CONTRAINDICATES],fails to develop.,na,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936090,7/14/2014 19:51:01,,1323061814,7/14/2014 19:50:37,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],induce,n/a,77,90,80,99,1,RO-has_finding_site,905057-FS1,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA
502936091,7/14/2014 17:33:57,,1322983217,7/14/2014 17:33:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],suggest,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 17:47:00,,1322995327,7/14/2014 17:45:41,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],"OSTEOPOROTIC BONE in OSTEOPOROSIS and fractures, not only bone mass changes,",N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 17:54:46,,1322998908,7/14/2014 17:54:37,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],that,n/a,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 17:57:41,,1323000314,7/14/2014 17:56:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],bone matrix,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:05:19,,1323003887,7/14/2014 18:04:40,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:11:18,,1323007815,7/14/2014 18:11:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS OSTEOPOROSIS,n/a,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:23:21,,1323013072,7/14/2014 18:22:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that OSTEOPOROSIS play a role in bone strength.,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:34:10,,1323017570,7/14/2014 18:33:13,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest that in,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:43:59,,1323022179,7/14/2014 18:42:25,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest OSTEOPOROSIS,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 18:59:07,,1323030949,7/14/2014 18:56:53,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest that,Na,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 19:02:29,,1323033302,7/14/2014 19:01:57,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BONE OSTEOPOROSIS,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 20:19:45,,1323075380,7/14/2014 20:19:10,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],found in,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 21:15:45,,1323103838,7/14/2014 21:15:08,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],alterations found,n/a,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 21:17:40,,1323104615,7/14/2014 21:17:20,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest,n/a,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936091,7/14/2014 21:25:10,,1323107967,7/14/2014 21:23:50,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],found in,N/A,37,108,90,120,1,RO-disease_has_primary_anatomic_site,902461-FS1,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502936092,7/14/2014 17:28:02,,1322978002,7/14/2014 17:27:16,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 17:34:21,,1322983583,7/14/2014 17:33:43,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 17:34:46,,1322983992,7/14/2014 17:34:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[MANIFESTATION],[MANIFESTATION],"detected,",N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 17:47:25,,1322995552,7/14/2014 17:47:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 17:49:50,,1322996583,7/14/2014 17:49:36,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],discontinue CAPTOPRIL,na,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 17:56:44,,1322999878,7/14/2014 17:56:35,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],soon,n/a,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 18:01:32,,1323001939,7/14/2014 18:01:20,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 18:07:02,,1323005798,7/14/2014 18:06:31,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 18:25:46,,1323013937,7/14/2014 18:22:57,neodev,1,17111650,USA,PA,Millersburg,174.59.14.30,[CONTRAINDICATES],[CONTRAINDICATES],"detected, discontinue",N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 18:31:23,,1323016463,7/14/2014 18:30:16,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],"is detected,",N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 18:58:12,,1323030284,7/14/2014 18:57:57,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PREGNANCY discontinue CAPTOPRIL,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 19:03:16,,1323033785,7/14/2014 19:02:58,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 19:52:18,,1323062337,7/14/2014 19:51:59,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],discontinue,n/a,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 20:34:28,,1323082924,7/14/2014 20:33:47,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,[CONTRAINDICATES],[CONTRAINDICATES],discontinue,na,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936092,7/14/2014 21:13:47,,1323102832,7/14/2014 21:13:15,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],discontinue,N/A,41,6,49,15,1,RO-contraindicated_drug,901494-FS1,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
502936093,7/14/2014 17:30:17,,1322979942,7/14/2014 17:29:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treating,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 17:34:39,,1322983869,7/14/2014 17:33:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is comparable to,[ASSOCIATED_WITH],106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 17:37:53,,1322987065,7/14/2014 17:37:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],effective for treating,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 17:57:08,,1323000055,7/14/2014 17:56:53,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],comparable to,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:06:57,,1323005713,7/14/2014 18:06:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANEMIA EPOETIN ALFA,n/a,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:08:53,,1323006625,7/14/2014 18:08:48,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:12:49,,1323008467,7/14/2014 18:12:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],ANEMIA comparable to EPOETIN ALFA,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:34:47,,1323017887,7/14/2014 18:33:56,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and is comparable to,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:41:36,,1323021066,7/14/2014 18:41:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],effective for treating comparable to,n/a,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:52:26,,1323026643,7/14/2014 18:51:26,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treating,none,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 18:59:37,,1323031323,7/14/2014 18:59:18,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treating,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 20:36:16,,1323083750,7/14/2014 20:35:37,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,[TREATS],[TREATS],treating,na,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 20:53:17,,1323092496,7/14/2014 20:52:52,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],for treating,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 21:08:33,,1323100512,7/14/2014 21:08:16,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",comparable,n/a,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936093,7/14/2014 21:13:14,,1323102610,7/14/2014 21:11:03,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],Darbepoetin administered and comparable to,N/A,106,181,111,193,1,RO-may_treat,907996-FS1,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
502936094,7/14/2014 17:16:22,,1322971465,7/14/2014 17:16:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],sensitization,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:16:52,,1322971689,7/14/2014 17:16:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],sensitization,Na,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:32:41,,1322982014,7/14/2014 17:31:52,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[LOCATION],[LOCATION],DERMATITIS of the SKIN,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:35:22,,1322984643,7/14/2014 17:34:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[LOCATION],[LOCATION],irritation sensitization,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:41:13,,1322990192,7/14/2014 17:40:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],sensitization of the,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:41:30,,1322990464,7/14/2014 17:39:41,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[LOCATION],[LOCATION],irritation or sensitization,na,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:41:41,,1322990649,7/14/2014 17:40:59,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]",resulting from irritation or sensitization of,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:56:12,,1322999662,7/14/2014 17:55:56,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[LOCATION],[LOCATION],of the,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 17:57:58,,1323000398,7/14/2014 17:57:50,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],Rhus,n/a,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:19:55,,1323011621,7/14/2014 18:19:31,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],DERMATITIS resulting from irritation of SKIN,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:31:58,,1323016760,7/14/2014 18:31:25,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],sensitization of the SKIN,n/a,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:46:33,,1323023425,7/14/2014 18:46:08,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],resulting,none,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:52:38,,1323026768,7/14/2014 18:52:01,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES] [SYMPTOM] [LOCATION],"[CAUSES]
[LOCATION]
[SYMPTOM]","DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol,",N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:53:34,,1323027210,7/14/2014 18:52:57,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],irritation or sensitization,na,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936094,7/14/2014 18:54:32,,1323027695,7/14/2014 18:54:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],sensitization SKIN,N/A,61,0,64,10,1,RO-has_finding_site,905059-FS1,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS
502936095,7/14/2014 17:14:11,,1322970357,7/14/2014 17:13:59,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LOVASTATIN (mevinolin),N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 17:43:29,,1322992354,7/14/2014 17:42:52,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",Treatment with,[ASSOCIATED_WITH] [TREATS],13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 17:47:22,,1322995516,7/14/2014 17:47:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],Treatment of,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 17:51:04,,1322997146,7/14/2014 17:50:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Treatment of with,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 18:00:19,,1323001369,7/14/2014 18:00:07,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],Treatment,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 18:09:05,,1323006724,7/14/2014 18:09:00,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 18:17:52,,1323010806,7/14/2014 18:17:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 18:36:58,,1323018825,7/14/2014 18:36:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],Treatment of with,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 18:46:46,,1323023513,7/14/2014 18:46:20,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 19:03:04,,1323033666,7/14/2014 19:02:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],Treatment with,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 20:09:37,,1323070128,7/14/2014 20:08:38,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],Treatment with,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 20:50:56,,1323091319,7/14/2014 20:50:40,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],Treatment of,N/A,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 21:16:59,,1323104353,7/14/2014 21:16:47,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",with,n/a,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 21:23:30,,1323107214,7/14/2014 21:23:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Treatment,n/a,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936095,7/14/2014 21:27:52,,1323109480,7/14/2014 21:27:18,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Treatment PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN,treats,13,56,49,66,1,RO-may_treat,907635-FS1,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN
502936096,7/14/2014 17:16:44,,1322971654,7/14/2014 17:16:33,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],products,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 17:22:22,,1322974200,7/14/2014 17:22:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 17:26:34,,1322976928,7/14/2014 17:25:50,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[TREATS],[TREATS],use of FACTOR VIII in the treatment of VON WILLEBRAND DISEASE.,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 17:47:59,,1322995764,7/14/2014 17:47:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 17:48:46,,1322996146,7/14/2014 17:48:22,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],in the treatment of,[TREATS],81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 18:02:43,,1323002443,7/14/2014 18:02:10,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in the treatment of,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 18:04:33,,1323003227,7/14/2014 18:04:15,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],in the treatment of,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 18:06:17,,1323005406,7/14/2014 18:06:04,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 18:21:27,,1323012276,7/14/2014 18:21:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],FACTOR VIII products in treatment of VON WILLEBRAND DISEASE.,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 18:44:04,,1323022227,7/14/2014 18:43:16,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treatment,none,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 20:26:12,,1323078575,7/14/2014 20:25:05,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],treatment of,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 20:49:11,,1323090314,7/14/2014 20:48:53,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],treatment,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 21:09:08,,1323100750,7/14/2014 21:08:53,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],treatment,n/a,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 21:19:33,,1323105416,7/14/2014 21:19:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment of,n/a,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936096,7/14/2014 21:27:52,,1323109489,7/14/2014 21:27:15,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treatment of,N/A,81,40,102,51,1,RO-may_treat,907758-FS1,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII
502936097,7/14/2014 17:12:23,,1322969435,7/14/2014 17:12:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],specific,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 17:14:20,,1322970428,7/14/2014 17:14:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],identifies,Na,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 17:30:55,,1322980441,7/14/2014 17:29:37,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[MANIFESTATION],[MANIFESTATION],SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 17:42:50,,1322991779,7/14/2014 17:42:15,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],that identifies a unique,[DIAGNOSE_BY_TEST_OR_DRUG],19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 18:01:06,,1323001753,7/14/2014 18:00:50,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[PART_OF],[PART_OF],SUBSET,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 18:06:02,,1323004686,7/14/2014 18:05:58,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 18:23:52,,1323013227,7/14/2014 18:23:26,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],that identifies a,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 18:44:58,,1323022617,7/14/2014 18:44:00,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) identifies SUBSET OF LUPUS ERYTHEMATOSUS.,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 19:57:41,,1323065009,7/14/2014 19:57:21,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],specific eruption identifies,n/a,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 20:10:46,,1323070660,7/14/2014 20:10:28,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],unique SUBSET,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 20:58:24,,1323095257,7/14/2014 20:57:48,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[MANIFESTATION],[MANIFESTATION],identifies a unique,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 21:11:03,,1323101691,7/14/2014 21:10:02,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],identifies,N/A,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 21:15:43,,1323103812,7/14/2014 21:15:28,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],identifies,n/a,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 21:20:17,,1323105755,7/14/2014 21:19:38,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],lupus specific eruption,n/a,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936097,7/14/2014 21:25:43,,1323108312,7/14/2014 21:23:54,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS lupus specific eruption identifies unique SUBSET OF LUPUS ERYTHEMATOSUS.,location,19,119,56,148,-1,RO-cause_of,900203-FS1,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
502936098,7/14/2014 17:23:18,,1322974764,7/14/2014 17:23:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,140209 Joshikou Keisatsu ep12v2,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 17:42:11,,1322991145,7/14/2014 17:41:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 17:50:06,,1322996681,7/14/2014 17:49:31,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated using the,[DIAGNOSE_BY_TEST_OR_DRUG],143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 17:51:27,,1322997364,7/14/2014 17:51:01,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,na,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 17:58:28,,1323000585,7/14/2014 17:58:08,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of global,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:03:23,,1323002761,7/14/2014 18:02:37,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated using,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:18:54,,1323011282,7/14/2014 18:18:34,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:34:10,,1323017571,7/14/2014 18:32:30,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],investigated,none,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:35:23,,1323018168,7/14/2014 18:34:52,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:39:23,,1323019932,7/14/2014 18:39:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],of global,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:51:53,,1323026335,7/14/2014 18:51:28,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated using,n/a,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 18:55:11,,1323028061,7/14/2014 18:54:37,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated,Na,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 19:08:54,,1323036909,7/14/2014 19:08:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated using,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 20:17:03,,1323073824,7/14/2014 20:15:54,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated using,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936098,7/14/2014 20:57:47,,1323094878,7/14/2014 20:57:23,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated,N/A,143,185,173,193,1,RO-has_finding_site,905062-FS1,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA
502936099,7/14/2014 17:13:57,,1322970145,7/14/2014 17:13:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],osteosarcoma,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 17:15:38,,1322971025,7/14/2014 17:15:24,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],different,Na,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 17:36:26,,1322985712,7/14/2014 17:36:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],with,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 17:54:35,,1322998834,7/14/2014 17:54:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],human,n/a,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 18:12:51,,1323008476,7/14/2014 18:12:40,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BONE MARROW LEUKEMIA,n/a,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 18:44:18,,1323022316,7/14/2014 18:43:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[OTHER],[OTHER],BONE MARROW with different types of LEUKEMIA,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 18:47:45,,1323024111,7/14/2014 18:46:20,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],co cultures,n/a,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 18:49:01,,1323024741,7/14/2014 18:48:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 18:57:56,,1323030131,7/14/2014 18:57:41,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BONE MARROW LEUKEMIA,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 19:02:25,,1323033218,7/14/2014 19:01:34,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[IS_A],[IS_A],with,none,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 19:10:33,,1323037787,7/14/2014 19:10:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],human cells with BONE MARROW,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 19:20:12,,1323043456,7/14/2014 19:19:36,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],osteosarcoma cells with BONE MARROW were studied.,NA,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 19:44:40,,1323058027,7/14/2014 19:44:11,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],BONE MARROW,na,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 20:00:28,,1323066300,7/14/2014 19:59:45,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CONTRAINDICATES],[CONTRAINDICATES],patients with different,n/a,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936099,7/14/2014 20:15:21,,1323072960,7/14/2014 20:14:15,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],cells with,N/A,78,152,88,160,1,RO-disease_has_primary_anatomic_site,902192-FS1,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA
502936100,7/14/2014 17:14:59,,1322970716,7/14/2014 17:14:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],treatment,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 17:35:24,,1322984663,7/14/2014 17:34:53,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],for the treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 17:45:53,,1322994805,7/14/2014 17:45:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for the treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 17:49:27,,1322996425,7/14/2014 17:49:07,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],treatment,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 17:56:54,,1322999943,7/14/2014 17:56:45,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diethylcarbamazine,n/a,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:00:31,,1323001451,7/14/2014 18:00:19,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],treatment,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:02:36,,1323002377,7/14/2014 18:02:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:08:23,,1323006392,7/14/2014 18:08:18,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:14:19,,1323009223,7/14/2014 18:14:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:18:32,,1323011114,7/14/2014 18:18:17,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],IVERMECTIN for treatment of ONCHOCERCIASIS,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:33:55,,1323017445,7/14/2014 18:33:30,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],for the treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:40:34,,1323020485,7/14/2014 18:40:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for the treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:56:22,,1323028926,7/14/2014 18:54:44,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],treatment,na,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 18:58:22,,1323030389,7/14/2014 18:57:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],for the treatment of,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936100,7/14/2014 19:05:35,,1323035162,7/14/2014 19:05:09,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],IVERMECTIN treatment ONCHOCERCIASIS,N/A,69,14,82,24,1,RO-may_treat,907881-FS1,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
502936101,7/14/2014 17:37:06,,1322986308,7/14/2014 17:36:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CONTRAINDICATES],[CONTRAINDICATES],but,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 17:56:59,,1322999983,7/14/2014 17:56:20,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PERIPHERAL PERIPHERAL,na,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 17:57:48,,1323000342,7/14/2014 17:57:26,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[LOCATION],[LOCATION],after injury,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 18:11:29,,1323007911,7/14/2014 18:11:19,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PERIPHERAL NERVES PERIPHERAL NEUROPATHIES,n/a,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 18:39:58,,1323020194,7/14/2014 18:38:54,prodege,1,9378607,GBR,H9,London,90.201.89.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"PERIPHERAL NERVES show spontaneous regenerative responses, after injury or PERIPHERAL NEUROPATHIES",n/a,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 18:53:53,,1323027345,7/14/2014 18:52:28,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment,none,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 18:54:56,,1323027896,7/14/2014 18:54:01,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],"PERIPHERAL NERVES show responses, PERIPHERAL NEUROPATHIES",N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 19:00:44,,1323032160,7/14/2014 19:00:13,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],NERVES NEUROPATHIES,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 19:03:41,,1323034019,7/14/2014 19:03:05,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],PERIPHERAL NERVES PERIPHERAL NEUROPATHIES,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 19:51:58,,1323062177,7/14/2014 19:51:03,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],"spontaneous regenerative responses,",n/a,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 20:28:02,,1323079532,7/14/2014 20:27:25,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],recovery after injury,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 20:48:52,,1323090142,7/14/2014 20:47:54,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[MANIFESTATION],[MANIFESTATION],"responses,",N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 21:25:51,,1323108381,7/14/2014 21:25:15,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],PERIPHERAL NERVES,n/a,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 21:35:41,,1323113785,7/14/2014 21:34:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],PERIPHERAL NERVES PERIPHERAL NEUROPATHIES,manifestation,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936101,7/14/2014 21:59:34,,1323127922,7/14/2014 21:59:06,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],PERIPHERAL NERVES PERIPHERAL NEUROPATHIES,N/A,0,88,16,111,1,RO-has_finding_site,905462-FS1,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
502936102,7/14/2014 17:10:14,,1322968309,7/14/2014 17:10:03,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],major symptoms of,N/a,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 17:14:39,,1322970576,7/14/2014 17:14:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],CARNITINE,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 17:40:31,,1322989481,7/14/2014 17:40:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],one of the major symptoms,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 17:50:54,,1322997068,7/14/2014 17:50:08,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[SYMPTOM],[SYMPTOM],is one of the major symptoms of,[SYMPTOM],0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 17:51:47,,1322997545,7/14/2014 17:51:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],symptoms,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 17:55:56,,1322999527,7/14/2014 17:54:51,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],symptoms,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 18:03:29,,1323002784,7/14/2014 18:02:36,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[SYMPTOM],[SYMPTOM],HYPERAMMONEMIA is one of the symptoms of PRIMARY CARNITINE DEFICIENCY,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 18:05:49,,1323004031,7/14/2014 18:05:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERAMMONEMIA PRIMARY CARNITINE DEFICIENCY,n/a,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 18:12:09,,1323008204,7/14/2014 18:11:48,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[SYMPTOM],[SYMPTOM],HYPERAMMONEMIA is major symptoms of PRIMARY CARNITINE DEFICIENCY,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 18:42:01,,1323021260,7/14/2014 18:41:05,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms,none,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 19:07:58,,1323036412,7/14/2014 19:07:27,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[SYMPTOM],[SYMPTOM],HYPERAMMONEMIA is symptoms PRIMARY CARNITINE DEFICIENCY,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 19:12:29,,1323038784,7/14/2014 19:12:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],major symptoms,N/A,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 19:20:56,,1323043883,7/14/2014 19:20:38,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],major symptoms,NA,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 19:22:31,,1323044780,7/14/2014 19:22:14,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SYMPTOM],[SYMPTOM],symptoms,na,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936102,7/14/2014 19:56:06,,1323064265,7/14/2014 19:55:54,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],symptoms,n/a,0,47,13,75,1,RO-has_manifestation,906433-FS1,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
502936103,7/14/2014 17:14:57,,1322970707,7/14/2014 17:14:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],"(i.e.,",N/a,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:30:38,,1322980229,7/14/2014 17:30:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],"(i.e.,",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:42:30,,1322991521,7/14/2014 17:41:54,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],"(i.e.,",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:45:09,,1322994442,7/14/2014 17:44:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],nature of the,N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:46:26,,1322995069,7/14/2014 17:45:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],showed,N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:47:42,,1322995684,7/14/2014 17:47:04,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",related to shock from other disease),[ASSOCIATED_WITH] [SYMPTOM],88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:47:44,,1322995705,7/14/2014 17:46:54,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e.,",na,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:54:02,,1322998592,7/14/2014 17:53:52,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],predictive,n/a,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:54:10,,1322998620,7/14/2014 17:52:58,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e.,",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 17:55:43,,1322999449,7/14/2014 17:55:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],"(i.e.,",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 18:11:42,,1323008003,7/14/2014 18:11:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],COLONIC ISCHEMIA SPONTANEOUS ISCHEMIC COLITIS,n/a,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 18:38:16,,1323019388,7/14/2014 18:37:52,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[IS_A],[IS_A],"COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS",n/a,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 18:52:45,,1323026822,7/14/2014 18:52:20,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],"(i.e.,",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 18:53:31,,1323027171,7/14/2014 18:52:39,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",N/A,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936103,7/14/2014 19:22:13,,1323044621,7/14/2014 19:21:33,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],"(i.e.,",Same term,88,64,115,80,-1,RO-cause_of,900053-FS1,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA
502936104,7/14/2014 17:13:00,,1322969710,7/14/2014 17:12:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 17:20:53,,1322973517,7/14/2014 17:20:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],induce,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 17:29:55,,1322979633,7/14/2014 17:29:31,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],response,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 17:51:26,,1322997359,7/14/2014 17:50:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],immune response,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 17:56:33,,1322999795,7/14/2014 17:56:13,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TYPHI TYPHOID,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 18:22:29,,1323012731,7/14/2014 18:21:51,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],SALMONELLA TYPHI to induce TYPHOID FEVER,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 18:42:03,,1323021297,7/14/2014 18:41:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],to induce a humoral immune response,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 19:01:56,,1323032898,7/14/2014 19:01:41,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SALMONELLA induce FEVER,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 19:13:14,,1323039217,7/14/2014 19:12:30,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],induce immune response,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 20:06:00,,1323068618,7/14/2014 20:05:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],induce,n/a,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 20:18:54,,1323075010,7/14/2014 20:18:29,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],induce a humoral immune response,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 20:55:06,,1323093432,7/14/2014 20:54:26,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess the ability of,N/A,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 21:07:37,,1323100089,7/14/2014 21:07:10,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],induce,n/a,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 21:09:50,,1323101097,7/14/2014 21:09:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],to induce immune response,n/a,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 21:37:53,,1323115123,7/14/2014 21:37:31,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],induce,n/a,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936104,7/14/2014 21:38:30,,1323115535,7/14/2014 21:37:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],(OMPs) of SALMONELLA TYPHI induce humoral immune response humans with TYPHOID FEVER,treats,105,173,120,186,1,RO-has_causative_agent,903564-FS1,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER
502936105,7/14/2014 17:14:20,,1322970421,7/14/2014 17:14:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],"significant,",N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:16:32,,1322971558,7/14/2014 17:16:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],and normal control lung,N/a,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:21:56,,1322974001,7/14/2014 17:21:14,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[LOCATION],[LOCATION],LUNG,N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:40:56,,1322989901,7/14/2014 17:40:12,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]","paired normal lung was significant,",[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:47:11,,1322995410,7/14/2014 17:46:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],LUNG,N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:55:44,,1322999469,7/14/2014 17:55:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,n/a,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:56:03,,1322999605,7/14/2014 17:55:36,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[LOCATION],[LOCATION],LUNG cancer,na,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 17:58:17,,1323000538,7/14/2014 17:58:10,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],normal,n/a,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 18:08:40,,1323006516,7/14/2014 18:08:35,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 18:14:01,,1323009060,7/14/2014 18:13:27,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],and paired normal lung,N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 18:36:18,,1323018566,7/14/2014 18:35:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[OTHER],[OTHER],LUNG cancer,N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 18:43:15,,1323021851,7/14/2014 18:42:03,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],between,none,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 18:51:36,,1323026172,7/14/2014 18:49:28,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.175,[LOCATION],[LOCATION],paired normal lung,Na,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 19:01:31,,1323032644,7/14/2014 19:00:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[LOCATION],[LOCATION],LUNG LUNG CANCER was,N/A,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936105,7/14/2014 19:34:47,,1323052564,7/14/2014 19:34:23,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],LUNG,na,162,233,165,244,1,RO-has_finding_site,905225-FS1,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER
502936106,7/14/2014 17:19:24,,1322972733,7/14/2014 17:19:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],led to,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:21:20,,1322973726,7/14/2014 17:21:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],development,Na,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:35:24,,1322984655,7/14/2014 17:35:08,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],development,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:39:10,,1322988257,7/14/2014 17:38:39,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],led to development of potent,[CAUSES],78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:43:49,,1322992711,7/14/2014 17:43:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[NONE],[NONE],N/A,unrelated,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:48:54,,1322996198,7/14/2014 17:48:20,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],led to development of potent ANTIEMETICS,na,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:54:34,,1322998823,7/14/2014 17:53:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],development of potent,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 17:55:07,,1322999067,7/14/2014 17:54:48,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],chemotherapy,n/a,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 18:17:37,,1323010700,7/14/2014 18:17:20,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],INDUCED NAUSEA AND VOMITING led to ANTIEMETICS,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 18:58:58,,1323030795,7/14/2014 18:58:13,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],NAUSEA VOMITING,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 19:07:58,,1323036419,7/14/2014 19:07:23,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],led to development of potent,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 19:14:53,,1323040106,7/14/2014 19:14:15,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[PREVENTS],[PREVENTS],led to development of,Na,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 21:17:10,,1323104431,7/14/2014 21:16:30,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],potent ANTIEMETICS,n/a,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 21:17:19,,1323104495,7/14/2014 21:17:01,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],led to development,n/a,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936106,7/14/2014 21:23:48,,1323107335,7/14/2014 21:23:02,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],identification led to development,N/A,78,135,104,146,1,RO-may_prevent,907406-FS1,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
502936107,7/14/2014 17:12:35,,1322969550,7/14/2014 17:12:23,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],controlling,N/a,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:14:02,,1322970186,7/14/2014 17:13:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],controlling,Na,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:15:58,,1322971200,7/14/2014 17:15:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],relation,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:20:31,,1322973338,7/14/2014 17:19:45,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:37:58,,1322987167,7/14/2014 17:37:18,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]",are considered in relation to its actions in controlling,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:53:57,,1322998565,7/14/2014 17:53:40,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],its actions in controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 17:54:27,,1322998794,7/14/2014 17:54:11,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],in controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:08:04,,1323006193,7/14/2014 18:07:58,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:13:03,,1323008555,7/14/2014 18:12:50,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],IBUPROFEN controlling INFLAMMATION,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:27:15,,1323014572,7/14/2014 18:26:38,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[PREVENTS],[PREVENTS],its actions in controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:33:12,,1323017227,7/14/2014 18:32:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],are considered in relation to its actions in controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:46:07,,1323023220,7/14/2014 18:45:17,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],controlling,none,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 18:58:43,,1323030660,7/14/2014 18:58:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],controlling,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 19:07:26,,1323036113,7/14/2014 19:06:55,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],IBUPROFEN controlling INFLAMMATION,N/A,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936107,7/14/2014 19:18:53,,1323042566,7/14/2014 19:18:05,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[TREATS],[TREATS],controlling,Na,103,36,114,45,1,RO-may_treat,908220-FS1,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN
502936108,7/14/2014 17:26:43,,1322977055,7/14/2014 17:26:31,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 17:46:07,,1322994913,7/14/2014 17:45:02,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],and placebo in,na,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 17:50:59,,1322997105,7/14/2014 17:50:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",evaluation of,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 17:53:22,,1322998334,7/14/2014 17:52:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],evaluation of in,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 17:55:17,,1322999177,7/14/2014 17:55:09,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],"paroxetine,",n/a,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 17:56:52,,1322999934,7/14/2014 17:56:33,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],in,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 18:05:06,,1323003768,7/14/2014 18:04:25,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,They are both symptons of panic disorder but are not necessarily related to each other.,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 18:38:19,,1323019404,7/14/2014 18:37:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo",N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 18:45:16,,1323022764,7/14/2014 18:44:06,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],and,none,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 19:00:47,,1323032249,7/14/2014 19:00:10,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],CLOMIPRAMINE in PANIC DISORDER,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 19:05:48,,1323035272,7/14/2014 19:05:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],CLOMIPRAMINE in PANIC DISORDER,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 19:56:51,,1323064687,7/14/2014 19:56:28,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],placebo,n/a,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 20:19:08,,1323075173,7/14/2014 20:18:54,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],evaluation of,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 20:55:34,,1323093631,7/14/2014 20:55:07,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation of,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936108,7/14/2014 21:02:48,,1323097635,7/14/2014 20:59:56,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],evaluation in,N/A,64,36,77,48,1,RO-may_treat,907891-FS1,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
502936109,7/14/2014 17:21:57,,1322974011,7/14/2014 17:21:45,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],progressive,Na,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 17:43:02,,1322991975,7/14/2014 17:42:16,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],both in progressive and ENDSTAGE,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 17:50:10,,1322996716,7/14/2014 17:49:28,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],both in,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 17:53:51,,1322998524,7/14/2014 17:53:41,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CONTRAINDICATES],[CONTRAINDICATES],progressive,n/a,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 17:55:35,,1322999371,7/14/2014 17:55:13,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both in progressive,na,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 18:42:28,,1323021471,7/14/2014 18:42:04,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both in progressive renal failure and,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 18:48:21,,1323024381,7/14/2014 18:47:23,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 18:53:06,,1323026944,7/14/2014 18:52:09,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANEMIA OF CHRONIC RENAL FAILURE both in ENDSTAGE RENAL FAILURE (ESRD.,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 18:54:48,,1323027815,7/14/2014 18:54:14,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both in,n/a,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 19:01:26,,1323032588,7/14/2014 19:00:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both in,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 19:13:13,,1323039210,7/14/2014 19:12:41,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],both in progressive renal failure and,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 19:57:19,,1323064901,7/14/2014 19:56:52,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],treatment progressive,n/a,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 20:07:14,,1323069120,7/14/2014 20:06:30,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],and,N/A,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 21:22:09,,1323106508,7/14/2014 21:21:32,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RENAL FAILURE,n/a,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936109,7/14/2014 21:31:55,,1323111791,7/14/2014 21:30:52,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],ANEMIA OF CHRONIC RENAL FAILURE both in ENDSTAGE RENAL FAILURE,is a,42,112,72,140,-1,RO-cause_of,900181-FS1,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD
502936110,7/14/2014 17:13:42,,1322970081,7/14/2014 17:13:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in case,N/a,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 17:28:25,,1322978329,7/14/2014 17:28:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],should be readily available,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 17:34:02,,1322983341,7/14/2014 17:33:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],reaction occurs.,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 17:40:15,,1322989253,7/14/2014 17:39:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],should be readily available,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 17:48:27,,1322995979,7/14/2014 17:47:49,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],should be readily available,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:01:47,,1323002026,7/14/2014 18:01:33,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],available in case,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:16:41,,1323010248,7/14/2014 18:16:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],EPINEPHRINE should be available in case ANAPHYLAXIS,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:31:24,,1323016481,7/14/2014 18:30:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],should be available in case allergic reaction occurs.,n/a,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:37:46,,1323019161,7/14/2014 18:37:20,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:44:57,,1323022601,7/14/2014 18:44:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],and other appropriate agents should be readily available in case ANAPHYLAXIS,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:56:23,,1323028943,7/14/2014 18:55:44,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[TREATS],[TREATS],appropriate agents,Na,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 18:59:59,,1323031598,7/14/2014 18:59:38,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],appropriate agents,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 19:43:06,,1323057155,7/14/2014 19:42:38,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],readily available,na,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 20:10:27,,1323070538,7/14/2014 20:10:06,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],in case,N/A,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936110,7/14/2014 21:07:09,,1323099879,7/14/2014 21:06:48,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],readily available in case,n/a,88,11,98,22,1,RO-may_treat,907651-FS1,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE
502936111,7/14/2014 17:41:31,,1322990496,7/14/2014 17:41:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],caused by,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 17:47:45,,1322995706,7/14/2014 17:46:31,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],Insulin resistance developing,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 18:01:19,,1323001850,7/14/2014 18:01:07,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],respond properly,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 18:06:20,,1323005411,7/14/2014 18:05:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]","TYPE 2 DIABETES INSULIN,",n/a,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 18:31:20,,1323016434,7/14/2014 18:30:29,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[PART_OF],[PART_OF],developing,none,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 18:40:16,,1323020371,7/14/2014 18:39:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],caused by the inability of insulin target tissues to respond properly to,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 18:53:52,,1323027337,7/14/2014 18:53:37,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],"DIABETES INSULIN,",N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 19:02:21,,1323033158,7/14/2014 19:01:32,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PREVENTS],[PREVENTS],"TYPE 2 DIABETES respond properly to INSULIN,",N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 19:11:49,,1323038425,7/14/2014 19:11:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],respond properly to,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 20:01:54,,1323066907,7/14/2014 20:00:30,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS] [ASSOCIATED_WITH] [CAUSES],"[TREATS]
[CAUSES]
[ASSOCIATED_WITH]",caused,n/a,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 20:56:41,,1323094262,7/14/2014 20:56:11,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],resistance is,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 21:21:31,,1323106218,7/14/2014 21:20:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],"respond to INSULIN,",n/a,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 21:31:24,,1323111487,7/14/2014 21:30:14,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],respond to,N/A,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 21:32:34,,1323112101,7/14/2014 21:31:39,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],risk factor for developing,na,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936111,7/14/2014 21:33:04,,1323112384,7/14/2014 21:31:56,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],"TYPE 2 DIABETES caused by inability insulin target tissues respond properly INSULIN,",causes,57,146,71,153,1,RO-may_treat,908348-FS1,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN
502936112,7/14/2014 17:15:08,,1322970791,7/14/2014 17:14:56,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment.,Na,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 17:15:08,,1322970794,7/14/2014 17:15:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],developed,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 17:35:56,,1322985190,7/14/2014 17:35:26,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 17:47:41,,1322995686,7/14/2014 17:47:26,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 17:54:20,,1322998706,7/14/2014 17:53:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SIDE_EFFECT],[SIDE_EFFECT],developed after initiation of treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:12:21,,1323008286,7/14/2014 18:11:55,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PARKINSON'S DISEASE AMANTADINE,n/a,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:23:58,,1323013287,7/14/2014 18:23:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],PARKINSON'S DISEASE after AMANTADINE treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:25:07,,1323013689,7/14/2014 18:24:23,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,"The disease was present before the treatment was used, so they are not necessarily related to each other.",23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:50:21,,1323025470,7/14/2014 18:49:41,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[SIDE_EFFECT] [TREATS],"[TREATS]
[SIDE_EFFECT]",A 61 year old man with PARKINSON'S DISEASE developed sudden onset visual impairment after initiation of AMANTADINE treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:52:08,,1323026481,7/14/2014 18:51:23,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CONTRAINDICATES],[CONTRAINDICATES],PARKINSON'S DISEASE (PD) after AMANTADINE,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:54:55,,1323027890,7/14/2014 18:54:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DISEASE developed treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 18:59:51,,1323031504,7/14/2014 18:59:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 20:23:39,,1323077337,7/14/2014 20:23:12,bitcoinget,1,25255063,GBR,V2,Glasgow,86.174.15.198,[CONTRAINDICATES],[CONTRAINDICATES],impairment after initiation of,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 21:12:59,,1323102508,7/14/2014 21:12:35,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],initiation of treatment.,n/a,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936112,7/14/2014 21:16:07,,1323103988,7/14/2014 21:15:11,bitcoinget,1,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treatment.,N/A,23,109,41,119,1,RO-may_treat,908349-FS1,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
502936113,7/14/2014 17:10:02,,1322968190,7/14/2014 17:09:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],manifestation of,N/a,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 17:28:38,,1322978542,7/14/2014 17:28:06,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],manifestation,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 17:28:46,,1322978672,7/14/2014 17:28:26,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],on the,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 17:35:43,,1322984981,7/14/2014 17:35:14,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],on the age of manifestation of,[MANIFESTATION],66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 17:44:41,,1322994082,7/14/2014 17:44:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF] [MANIFESTATION],"[MANIFESTATION]
[PART_OF]",manifestation of,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:06:25,,1323005446,7/14/2014 18:03:30,prodege,1,2767509,CAN,BC,Victoria,96.54.172.117,[ASSOCIATED_WITH],[ASSOCIATED_WITH],influence of alterations in BRAIN on EPILEPSY,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:09:20,,1323006867,7/14/2014 18:09:14,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:13:02,,1323008553,7/14/2014 18:12:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRAIN EPILEPSY,n/a,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:21:08,,1323012146,7/14/2014 18:20:47,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[MANIFESTATION],[MANIFESTATION],organic alterations in the BRAIN manifestation of EPILEPSY,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:41:38,,1323021088,7/14/2014 18:41:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],on the age of manifestation of EPILEPSY,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:47:23,,1323023910,7/14/2014 18:46:47,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[LOCATION],[LOCATION],organic alterations in the BRAIN,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:51:18,,1323025993,7/14/2014 18:51:09,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BRAIN,N/A,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 18:54:43,,1323027772,7/14/2014 18:54:14,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],manifestation,na,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 19:05:14,,1323035001,7/14/2014 19:04:55,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],manifestation,none,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936113,7/14/2014 19:18:02,,1323042009,7/14/2014 19:17:25,clixsense,1,15189335,GBR,A7,Birmingham,94.197.121.232,[LOCATION],[LOCATION],alterations in the,Na,66,103,70,111,1,RO-disease_has_primary_anatomic_site,902366-FS1,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
502936114,7/14/2014 17:14:49,,1322970647,7/14/2014 17:14:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],TACHYCARDIA,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:15:54,,1322971176,7/14/2014 17:15:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],chronic coronary,Na,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:29:52,,1322979595,7/14/2014 17:29:38,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:35:46,,1322985022,7/14/2014 17:35:25,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],To determine,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:37:41,,1322986812,7/14/2014 17:36:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[IS_A],[IS_A],TACHYCARDIA,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:54:12,,1322998651,7/14/2014 17:51:56,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],"patients with inducible, SUSTAINED VENTRICULAR",na,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 17:55:29,,1322999321,7/14/2014 17:55:19,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],preventing,n/a,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 18:07:44,,1323006045,7/14/2014 18:07:39,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 18:09:57,,1323007106,7/14/2014 18:09:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIA SUSTAINED VENTRICULAR TACHYCARDIA,n/a,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 18:39:04,,1323019774,7/14/2014 18:38:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 19:23:13,,1323045211,7/14/2014 19:22:35,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIA TACHYCARDIA,NA,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 20:35:36,,1323083411,7/14/2014 20:34:29,instagc,1,19602039,USA,WA,Bellevue,50.135.214.140,[PART_OF],[PART_OF],"15 patients with inducible,",na,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 21:12:00,,1323102113,7/14/2014 21:11:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TACHYCARDIA,n//a,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 21:37:34,,1323114916,7/14/2014 21:36:31,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],TACHYCARDIA SUSTAINED VENTRICULAR TACHYCARDIA chronic coronary artery disease,manifestation,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936114,7/14/2014 22:00:10,,1323128248,7/14/2014 21:59:35,neodev,1,21405167,USA,MD,Glen Burnie,69.137.237.73,[IS_A],[IS_A],TACHYCARDIA SUSTAINED VENTRICULAR TACHYCARDIA,N/A,208,248,218,281,-1,RO-has_definitional_manifestation,904545-FS1,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
502936115,7/14/2014 17:15:27,,1322970920,7/14/2014 17:15:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],differences,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 17:40:27,,1322989426,7/14/2014 17:39:44,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[CAUSES],[CAUSES],cause,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 17:49:34,,1322996485,7/14/2014 17:48:55,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[CAUSES],[CAUSES],to cause,na,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 17:55:50,,1322999490,7/14/2014 17:55:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms,n/a,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 18:02:18,,1323002261,7/14/2014 18:01:26,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CONTRAINDICATES],[CONTRAINDICATES],to cause an ADVERSE DRUG REACTION,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 18:05:37,,1323003993,7/14/2014 18:05:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUGS ADVERSE DRUG REACTION,n/a,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 18:06:30,,1323005460,7/14/2014 18:06:26,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 18:55:10,,1323028057,7/14/2014 18:54:56,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUGS ADVERSE DRUG,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 19:04:28,,1323034551,7/14/2014 19:04:07,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],cause,none,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 19:23:37,,1323045404,7/14/2014 19:23:14,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CAUSES],[CAUSES],cause,NA,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 19:59:44,,1323065979,7/14/2014 19:59:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT] [SYMPTOM],"[SYMPTOM]
[SIDE_EFFECT]",symptoms,n/a,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 20:15:53,,1323073262,7/14/2014 20:15:22,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],cause an,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 21:00:29,,1323096426,7/14/2014 20:59:57,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],reported to cause,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 21:03:47,,1323098184,7/14/2014 21:03:24,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],cause,n/a,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936115,7/14/2014 21:10:02,,1323101228,7/14/2014 21:09:19,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CAUSES],[CAUSES],cause,N/A,99,126,103,147,1,RO-has_causative_agent,903731-FS1,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION
502936116,7/14/2014 17:16:39,,1322971615,7/14/2014 17:16:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Successful dissolution,Na,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 17:45:45,,1322994736,7/14/2014 17:44:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],dissolution of gallstones,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 17:50:40,,1322996979,7/14/2014 17:49:51,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],dissolution with,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 17:51:45,,1322997525,7/14/2014 17:51:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],develop,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 18:10:45,,1323007552,7/14/2014 18:10:22,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],Successful dissolution,na,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 18:45:00,,1323022627,7/14/2014 18:44:23,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[TREATS],[TREATS],Successful dissolution of gallstones with,Na,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 18:45:22,,1323022838,7/14/2014 18:45:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SIDE_EFFECT],[SIDE_EFFECT],occurs rarely in patients with calcified,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 18:45:40,,1323023016,7/14/2014 18:44:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],"treatment,",n/a,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 18:49:24,,1323024931,7/14/2014 18:48:04,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],Successful dissolution URSODIOL GALLSTONES,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 19:05:18,,1323035015,7/14/2014 19:04:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurs in patients with GALLSTONES,N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 19:20:36,,1323043687,7/14/2014 19:20:13,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],Successful dissolution,IS TREATED BY,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 19:54:41,,1323063681,7/14/2014 19:54:22,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",occurs,n/a,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 20:06:29,,1323068827,7/14/2014 20:05:44,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],"treatment,",N/A,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 21:02:13,,1323097292,7/14/2014 21:01:52,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],with,n/a,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936116,7/14/2014 21:13:09,,1323102571,7/14/2014 21:12:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Successful dissolution,n/a,92,42,101,50,1,RO-may_treat,907935-FS1,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL
502936117,7/14/2014 17:16:52,,1322971680,7/14/2014 17:16:33,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM] [IS_A],"[SYMPTOM]
[IS_A]",is one of the major,N/a,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 17:18:09,,1322972251,7/14/2014 17:17:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],major COMPLICATIONS,Na,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 17:37:32,,1322986689,7/14/2014 17:37:07,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],major COMPLICATIONS,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 17:49:07,,1322996300,7/14/2014 17:48:51,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],is one of,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 17:49:54,,1322996617,7/14/2014 17:49:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],is one of the major,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 18:06:24,,1323005442,7/14/2014 18:06:18,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 18:36:03,,1323018461,7/14/2014 18:35:24,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",ECTOPIC PREGNANCY is one of major COMPLICATIONS OF PREGNANCY,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 19:03:08,,1323033726,7/14/2014 19:02:26,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],is,none,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 19:21:27,,1323044195,7/14/2014 19:20:01,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],major,Na,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 19:21:31,,1323044243,7/14/2014 19:20:57,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],one of the major,NA,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 19:56:27,,1323064427,7/14/2014 19:56:07,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],COMPLICATIONS,n/a,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 20:47:52,,1323089610,7/14/2014 20:47:03,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],major,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 21:16:26,,1323104125,7/14/2014 21:16:10,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SIDE_EFFECT],[SIDE_EFFECT],one of the major,n/a,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 21:22:58,,1323106892,7/14/2014 21:22:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],is one,n/a,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936117,7/14/2014 21:23:01,,1323106911,7/14/2014 21:21:52,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SIDE_EFFECT],[SIDE_EFFECT],COMPLICATIONS OF,N/A,38,0,63,17,-1,RO-disease_has_finding,901953-FS1,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
502936118,7/14/2014 17:17:41,,1322972062,7/14/2014 17:17:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],group,ANa,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 17:31:18,,1322980814,7/14/2014 17:31:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 17:35:07,,1322984368,7/14/2014 17:34:47,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],SITU,N/A,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 17:39:39,,1322988624,7/14/2014 17:37:39,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[SYMPTOM],[SYMPTOM],with a,na,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 17:44:11,,1322993127,7/14/2014 17:43:30,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"was used,",[DIAGNOSE_BY_TEST_OR_DRUG],164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 17:52:17,,1322997828,7/14/2014 17:51:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],negative Papanicolaou smear,N/A,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 18:05:43,,1323004013,7/14/2014 18:05:39,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 18:11:03,,1323007711,7/14/2014 18:10:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,n/a,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 19:03:38,,1323033991,7/14/2014 19:02:22,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 19:13:43,,1323039474,7/14/2014 19:13:16,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 19:13:51,,1323039555,7/14/2014 19:13:15,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],65 with 11 with,N/A,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 19:58:24,,1323065391,7/14/2014 19:57:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 21:12:38,,1323102363,7/14/2014 21:12:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],with a,n/a,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 21:13:15,,1323102618,7/14/2014 21:13:00,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],with a,n/a,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936118,7/14/2014 21:39:38,,1323116274,7/14/2014 21:38:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],group with negative Papanicolaou smear SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU,associated with,164,191,179,208,-1,RO-disease_has_finding,901954-FS1,"In the group with a negative Papanicolaou smear and for whom the cotton tipped applicator plus colposcopy was used, there were 214 with a mild dysplasia, 65 with a SEVERE DYSPLASIA 11 with a CARCINOMA IN SITU and 7 with an invasive carcinoma.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502936119,7/14/2014 17:22:30,,1322974249,7/14/2014 17:22:00,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],treatment,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 17:23:28,,1322974890,7/14/2014 17:22:50,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[TREATS],[TREATS],MELPHALAN as treatment for MULTIPLE MYELOMA:,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 17:56:13,,1322999676,7/14/2014 17:56:03,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],treatment,n/a,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:07:31,,1323005986,7/14/2014 18:07:16,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:32:29,,1323016968,7/14/2014 18:31:21,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treatment,none,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:45:19,,1323022787,7/14/2014 18:44:57,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],treatment,na,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:46:01,,1323023182,7/14/2014 18:45:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA:,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:49:40,,1323025088,7/14/2014 18:49:02,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA:,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:54:14,,1323027545,7/14/2014 18:53:57,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment for,n/a,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 18:57:26,,1323029751,7/14/2014 18:57:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MELPHALAN MYELOMA:,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 19:00:07,,1323031676,7/14/2014 18:59:51,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment for,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 19:11:11,,1323038146,7/14/2014 19:10:49,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treatment for,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 19:22:37,,1323044836,7/14/2014 19:22:05,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[TREATS],[TREATS],as treatment,Na,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 20:03:39,,1323067575,7/14/2014 20:01:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],treatment,n/a,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936119,7/14/2014 20:17:49,,1323074312,7/14/2014 20:17:04,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],treatment for,N/A,75,32,90,41,1,RO-may_treat,907938-FS1,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
502936120,7/14/2014 17:17:39,,1322972042,7/14/2014 17:17:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],Exacerbation of disease,N/a,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:23:39,,1322974958,7/14/2014 17:23:21,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:32:09,,1322981593,7/14/2014 17:31:27,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",disease for which,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:38:48,,1322987847,7/14/2014 17:38:25,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],being used,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:40:37,,1322989614,7/14/2014 17:39:51,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],is being used,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:48:17,,1322995876,7/14/2014 17:47:46,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],DRUG TOXICITY DRUG,na,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:55:18,,1322999176,7/14/2014 17:54:21,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,This is just a list of questions.,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 17:57:40,,1323000318,7/14/2014 17:57:33,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],Elements:,n/a,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 18:48:46,,1323024614,7/14/2014 18:48:21,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[OTHER],[OTHER],assessment.,none,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 18:52:23,,1323026616,7/14/2014 18:51:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],Evidence of DRUG TOXICITY,n/a,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 18:54:14,,1323027562,7/14/2014 18:53:53,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],TOXICITY,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 19:22:33,,1323044794,7/14/2014 19:22:00,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],na,This is just a bunch of random phrases with question marks after them. There is no context.,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 19:45:08,,1323058263,7/14/2014 19:44:41,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],Evidence,na,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 20:20:55,,1323075979,7/14/2014 20:19:45,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CONTRAINDICATES],[CONTRAINDICATES],Exacerbation of disease,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936120,7/14/2014 20:56:10,,1323093974,7/14/2014 20:55:35,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],is being used,N/A,298,298,301,311,-1,RO-has_causative_agent,903983-FS1,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY
502936121,7/14/2014 17:12:42,,1322969599,7/14/2014 17:12:35,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],(43%),N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:22:07,,1322974086,7/14/2014 17:21:44,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:32:08,,1322981570,7/14/2014 17:31:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:33:09,,1322982493,7/14/2014 17:32:22,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],was present,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:38:37,,1322987702,7/14/2014 17:38:00,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was present in 99 (43%),[DIAGNOSE_BY_TEST_OR_DRUG],69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:46:03,,1322994888,7/14/2014 17:45:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 17:46:25,,1322995067,7/14/2014 17:46:08,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA and CARCINOMA IN SITU,na,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 18:07:37,,1323006012,7/14/2014 18:07:32,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 18:09:44,,1323007025,7/14/2014 18:09:33,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,n/a,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 18:25:30,,1323013835,7/14/2014 18:25:07,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 18:54:35,,1323027720,7/14/2014 18:54:11,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 19:09:56,,1323037454,7/14/2014 19:09:36,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,different terms,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 20:05:18,,1323068292,7/14/2014 20:04:24,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present,n/a,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 20:52:51,,1323092281,7/14/2014 20:52:14,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],was present in,N/A,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936121,7/14/2014 21:06:47,,1323099626,7/14/2014 21:06:27,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,69,90,84,107,-1,RO-disease_has_finding,901966-FS1,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU
502936122,7/14/2014 17:31:00,,1322980508,7/14/2014 17:30:15,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],experienced,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 17:31:27,,1322980945,7/14/2014 17:30:47,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[SYMPTOM],[SYMPTOM],participants experienced a ROBUST REDUCTION IN PAIN,na,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 17:34:25,,1322983620,7/14/2014 17:34:03,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],experienced,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 17:58:28,,1323000577,7/14/2014 17:58:18,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],lamotrigine,n/a,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 18:13:31,,1323008807,7/14/2014 18:13:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THE TREATMENT OF participants,n/a,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 18:16:01,,1323010013,7/14/2014 18:15:34,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],THE TREATMENT OF VULVODYNIA FOUND THAT participants experienced ROBUST REDUCTION IN PAIN,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 18:47:42,,1323024105,7/14/2014 18:45:42,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[ASSOCIATED_WITH],[ASSOCIATED_WITH],experienced,Na,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 18:57:56,,1323030132,7/14/2014 18:56:16,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced ROBUST REDUCTION IN PAIN,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 18:59:27,,1323031230,7/14/2014 18:58:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],participants experienced a,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 19:01:49,,1323032836,7/14/2014 19:00:38,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],experienced,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 19:30:09,,1323049519,7/14/2014 19:29:22,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],experienced REDUCTION,na,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 20:14:13,,1323072429,7/14/2014 20:13:26,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],participants experienced,N/A,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 21:15:26,,1323103663,7/14/2014 21:13:16,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],experienced,n/a,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 21:18:59,,1323105138,7/14/2014 21:18:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],TREATMENT,n/a,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936122,7/14/2014 21:29:55,,1323110699,7/14/2014 21:29:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],THE TREATMENT OF VULVODYNIA FOUND THAT 17 experienced ROBUST REDUCTION IN PAIN,treats,124,49,147,90,-1,RO-has_definitional_manifestation,904958-FS1,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
502936123,7/14/2014 17:18:03,,1322972219,7/14/2014 17:17:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],FOR THE TREATMENT of,N/a,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 17:26:11,,1322976669,7/14/2014 17:25:51,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],TREATMENT,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 17:28:19,,1322978266,7/14/2014 17:27:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FDA approval,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 17:28:34,,1322978445,7/14/2014 17:27:26,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[NONE],[NONE],na,The option for [TREATED_BY] is not there and would have been appropriate here.,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 17:31:50,,1322981328,7/14/2014 17:30:57,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[TREATS],[TREATS],FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR TREATMENT of MULTIPLE MYELOMA,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 17:44:09,,1322993102,7/14/2014 17:43:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],exemplified by,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 18:05:55,,1323004162,7/14/2014 18:05:07,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],FOR THE TREATMENT of,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 18:08:29,,1323006437,7/14/2014 18:08:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT MULTIPLE MYELOMA,n/a,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 18:30:03,,1323015855,7/14/2014 18:29:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],TREATMENT of,n/a,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 18:52:00,,1323026406,7/14/2014 18:51:20,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 18:59:17,,1323031039,7/14/2014 18:58:59,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],MULTIPLE,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 19:04:06,,1323034247,7/14/2014 19:03:40,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],TREATMENT,none,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 19:13:43,,1323039477,7/14/2014 19:13:15,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 19:46:18,,1323058918,7/14/2014 19:45:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],TREATMENT,na,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936123,7/14/2014 19:49:52,,1323061131,7/14/2014 19:49:35,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],relapsed/refractory,n/a,180,101,195,156,1,RO-may_treat,908005-FS1,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
502936124,7/14/2014 17:09:26,,1322967826,7/14/2014 17:09:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],in the heavily,N/a,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:25:49,,1322976410,7/14/2014 17:23:29,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in DEPENDENT SMOKERS cimetidine did not alter NICOTINE elimination.,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:34:53,,1322984113,7/14/2014 17:33:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CONTRAINDICATES],[CONTRAINDICATES],did not appear,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:49:30,,1322996457,7/14/2014 17:48:48,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",did not appear to alter,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:56:54,,1322999941,7/14/2014 17:55:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Contrary to previous findings,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:57:05,,1323000022,7/14/2014 17:56:55,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],clearance,n/a,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 17:57:14,,1323000083,7/14/2014 17:55:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],DEPENDENT,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:07:41,,1323006026,7/14/2014 18:06:38,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],alter elimination.,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:20:46,,1323011998,7/14/2014 18:20:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],DEPENDENT SMOKERS did not appear to alter NICOTINE elimination.,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:34:21,,1323017684,7/14/2014 18:33:33,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],cimetidine decreased the total body clearance of nicotine by 30%,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:37:48,,1323019180,7/14/2014 18:36:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,"It says it did not alter Nicotine elimination, therefore there is no link between the two terms.",204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:50:17,,1323025399,7/14/2014 18:49:20,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",heavily,none,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 18:53:26,,1323027126,7/14/2014 18:53:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],SMOKERS NICOTINE,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 19:02:24,,1323033217,7/14/2014 19:01:50,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not appear to alter,N/A,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936124,7/14/2014 19:03:01,,1323033640,7/14/2014 19:01:39,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[CAUSES],[CAUSES],in the heavily DEPENDENT,Na,204,151,211,168,-1,RO-has_causative_agent,903754-FS1,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS
502936125,7/14/2014 17:17:19,,1322971880,7/14/2014 17:17:08,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],TOLERANCE,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 17:33:29,,1322982829,7/14/2014 17:31:49,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held,na,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 17:36:54,,1322986126,7/14/2014 17:36:01,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[NONE],[NONE],N/A,highlighted words are not coherrant,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 17:39:50,,1322988792,7/14/2014 17:39:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],constant by,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 17:55:40,,1322999413,7/14/2014 17:54:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],when,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 18:04:25,,1323003171,7/14/2014 18:03:50,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,"""Even when"" implies a different circumstance but not necessarily a relationship.",153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 18:08:48,,1323006562,7/14/2014 18:08:41,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 18:08:54,,1323006630,7/14/2014 18:08:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN ADMINISTRATION OF THE DRUG AFTER THE TEST.,n/a,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 18:35:17,,1323018135,7/14/2014 18:34:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],when drug exposure is held constant by,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 18:44:19,,1323022323,7/14/2014 18:42:59,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]",When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 19:05:31,,1323035129,7/14/2014 19:04:59,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[TREATS],[TREATS],drug exposure is held constant,N/A,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 20:04:23,,1323067902,7/14/2014 20:03:39,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],exposure,n/a,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 21:10:48,,1323101586,7/14/2014 21:09:50,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],When,n/a,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 21:12:34,,1323102345,7/14/2014 21:10:23,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],drug exposure held,n/a,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936125,7/14/2014 21:29:00,,1323110194,7/14/2014 21:27:53,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure held constant ADMINISTRATION OF THE DRUG AFTER THE TEST.,diagnose by test or drug,153,68,193,113,-1,RO-has_causative_agent,903512-FS1,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
502936126,7/14/2014 17:15:22,,1322970887,7/14/2014 17:15:09,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],sectioning,Na,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 17:38:24,,1322987537,7/14/2014 17:38:00,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[OTHER],[OTHER],not to be,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 17:50:23,,1322996832,7/14/2014 17:49:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was identified as,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 17:50:48,,1322997033,7/14/2014 17:49:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FOLLICULAR,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 17:53:39,,1322998463,7/14/2014 17:53:23,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as,n/a,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 18:09:14,,1323006828,7/14/2014 18:08:17,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed not to be a,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 18:32:27,,1323016963,7/14/2014 18:31:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 19:09:34,,1323037254,7/14/2014 19:08:57,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,separate terms,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 19:25:15,,1323046340,7/14/2014 19:24:49,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[OTHER],[OTHER],showed not to be,Na,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 20:28:48,,1323080023,7/14/2014 20:28:04,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],with,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 20:54:25,,1323093094,7/14/2014 20:53:48,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],serial sectioning,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 21:08:15,,1323100387,7/14/2014 21:07:39,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],not to be,n/a,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 21:16:28,,1323104140,7/14/2014 21:15:47,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],with,n/a,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 21:30:13,,1323110852,7/14/2014 21:29:21,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CONTRAINDICATES],[CONTRAINDICATES],showed not to be,N/A,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936126,7/14/2014 21:38:11,,1323115324,7/14/2014 21:37:54,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],systematic,n/a,87,171,112,188,-1,RO-disease_has_finding,901731-FS1,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
502936127,7/14/2014 17:16:10,,1322971304,7/14/2014 17:16:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],SALMONELLAE,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 17:17:07,,1322971799,7/14/2014 17:16:52,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],the NUMBER of,N/a,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 17:19:29,,1322972827,7/14/2014 17:19:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[IS_A],[IS_A],NUMBER,Na,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 17:29:00,,1322978815,7/14/2014 17:28:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 17:41:11,,1322990186,7/14/2014 17:40:31,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[OTHER],[OTHER],of,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 17:47:02,,1322995341,7/14/2014 17:46:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NUMBER of per 100 ml remains almost constant.,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 18:08:29,,1323006435,7/14/2014 18:08:24,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,nas,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 18:46:19,,1323023324,7/14/2014 18:45:41,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NUMBER of,n/a,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 18:50:06,,1323025336,7/14/2014 18:49:25,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF],[PART_OF],NUMBER of SALMONELLAE,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 19:02:23,,1323033205,7/14/2014 19:01:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],NUMBER SALMONELLAE,Number is quantitative,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 20:25:04,,1323078000,7/14/2014 20:24:19,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],of,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 20:49:39,,1323090604,7/14/2014 20:49:12,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],presence of,N/A,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 21:17:57,,1323104730,7/14/2014 21:17:42,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],of,n/a,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 21:20:52,,1323105957,7/14/2014 21:20:19,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NUMBER of,n/a,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936127,7/14/2014 21:27:17,,1323109174,7/14/2014 21:25:45,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],effluent the NUMBER SALMONELLAE per 100,other - indicates an amount,211,201,221,207,-1,RO-has_causative_agent,903637-FS1,With regard to the presence of salmonellae in surface waters receiving effluent it was shown that from the immediate vicinity of the plant to 250 m downstream from the site of drainage of effluent the NUMBER of SALMONELLAE per 100 ml remains almost constant.,SALMONELLAE,NUMBER
502936128,7/14/2014 17:16:12,,1322971315,7/14/2014 17:15:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],six,Na,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 17:26:59,,1322977277,7/14/2014 17:26:44,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had,N/A,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 17:27:25,,1322977600,7/14/2014 17:26:24,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA,na,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 17:29:36,,1322979330,7/14/2014 17:27:46,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[NONE],[NONE],N/A,"They are both included in a list of outcomes found in patients, but no connection is expressed between them.",248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 17:33:28,,1322982807,7/14/2014 17:33:12,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[MANIFESTATION],[MANIFESTATION],six had,N/A,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 17:45:41,,1322994681,7/14/2014 17:44:20,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,The passage does not provide any evidence that the two are related as it is only listing various medical issues without giving any relation.,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 18:09:13,,1323006798,7/14/2014 18:09:06,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 18:33:29,,1323017317,7/14/2014 18:32:59,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,Some patients had one condition and some had another; the two are not necessarily related.,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 18:38:25,,1323019460,7/14/2014 18:37:48,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[NONE],[NONE],N/A,I cannot find any relations.,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 18:45:39,,1323023012,7/14/2014 18:45:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU,N/A,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 18:59:17,,1323031040,7/14/2014 18:58:50,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 19:03:39,,1323034006,7/14/2014 19:03:10,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],had,none,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 19:08:36,,1323036761,7/14/2014 19:08:19,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],six had,N/A,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 19:22:03,,1323044524,7/14/2014 19:21:28,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],six had,Na,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936128,7/14/2014 19:50:27,,1323061504,7/14/2014 19:48:50,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],"dysplasia,",na,248,273,263,299,-1,RO-disease_has_finding,901857-FS1,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
502936129,7/14/2014 17:18:18,,1322972335,7/14/2014 17:18:04,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],due to,N/a,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:21:44,,1322973910,7/14/2014 17:21:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],patients,Na,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:26:22,,1322976791,7/14/2014 17:25:32,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[NONE],[NONE],na,2 patients with separate conditions.,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:42:13,,1322991176,7/14/2014 17:41:16,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],due to,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:49:26,,1322996424,7/14/2014 17:49:09,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the other,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:49:43,,1322996557,7/14/2014 17:49:18,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],presenting with,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 17:58:38,,1323000632,7/14/2014 17:58:29,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],the,n/a,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 18:09:31,,1323006935,7/14/2014 18:08:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONONUCLEOSIS EPSTEIN BARR VIRUS (EBV,n/a,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 18:17:18,,1323010543,7/14/2014 18:16:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,"Two different, unrelated conditions",87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 18:54:13,,1323027544,7/14/2014 18:53:36,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],due to,na,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 19:01:02,,1323032352,7/14/2014 19:00:45,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MONONUCLEOSIS VIRUS,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 19:05:09,,1323034920,7/14/2014 19:04:11,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],MONONUCLEOSIS due to EPSTEIN BARR VIRUS,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 19:12:08,,1323038587,7/14/2014 19:11:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],due to,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 20:59:56,,1323096155,7/14/2014 20:59:36,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],presenting with,N/A,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936129,7/14/2014 21:04:39,,1323098691,7/14/2014 21:03:48,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],due to,n/a,87,18,109,31,1,RO-has_causative_agent,903519-FS1,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
502936130,7/14/2014 17:13:37,,1322970054,7/14/2014 17:13:29,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],treated,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:17:22,,1322971906,7/14/2014 17:17:11,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treated,Na,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:17:22,,1322971911,7/14/2014 17:17:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],were treated with,N/a,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:19:35,,1322972854,7/14/2014 17:19:05,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],treated,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:29:12,,1322978951,7/14/2014 17:28:35,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[NONE],[NONE],na,no option for Treated by to select.,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:36:09,,1322985466,7/14/2014 17:35:46,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],were treated with,[TREATS],41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:55:30,,1322999326,7/14/2014 17:55:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",same highly,n/a,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 17:57:49,,1323000347,7/14/2014 17:57:41,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],same,n/a,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 18:00:06,,1323001242,7/14/2014 17:59:54,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],treated,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 18:12:29,,1323008318,7/14/2014 18:12:11,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],TYPE 1 DIABETES treated with BOVINE ISOPHANE INSULIN,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 18:24:23,,1323013416,7/14/2014 18:23:53,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[PREVENTS],[PREVENTS],were treated with the same highly purified,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 18:35:45,,1323018323,7/14/2014 18:35:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],were treated with the same highly purified,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 18:56:59,,1323029392,7/14/2014 18:56:39,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES INSULIN,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 19:04:53,,1323034779,7/14/2014 19:04:33,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treated,none,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936130,7/14/2014 19:09:10,,1323037103,7/14/2014 19:08:54,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treated with,N/A,41,100,55,123,1,RO-may_treat,908014-FS1,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN
502936131,7/14/2014 17:23:16,,1322974754,7/14/2014 17:22:34,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[SYMPTOM],[SYMPTOM],rapid intermediate slow,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 17:27:52,,1322977926,7/14/2014 17:27:31,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],intermediate,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 17:29:20,,1322979079,7/14/2014 17:29:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],intermediate,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 17:45:07,,1322994432,7/14/2014 17:44:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION] [CONTRAINDICATES],"[MANIFESTATION]
[CONTRAINDICATES]",intermediate in,[MANIFESTATION] [CONTRAINDICATES],13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 17:50:59,,1322997103,7/14/2014 17:50:35,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],intermediate in POLYCYSTIC KIDNEY DISEASE,na,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 17:57:22,,1323000135,7/14/2014 17:57:06,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],intermediate,n/a,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 18:01:25,,1323001908,7/14/2014 18:00:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],FAILURE is intermediate in,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 18:06:37,,1323005518,7/14/2014 18:05:55,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,"Kidney failure is part of all conditions, but the conditions are not related to one another.",13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 18:14:35,,1323009317,7/14/2014 18:14:17,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],KIDNEY FAILURE is POLYCYSTIC KIDNEY DISEASE,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 18:39:06,,1323019780,7/14/2014 18:38:27,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[IS_A],[IS_A],"KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 18:48:02,,1323024272,7/14/2014 18:47:01,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],KIDNEY FAILURE is intermediate in POLYCYSTIC KIDNEY DISEASE,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 19:13:14,,1323039215,7/14/2014 19:12:36,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],intermediate in,Na,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 20:24:19,,1323077629,7/14/2014 20:23:56,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],intermediate in,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 20:51:42,,1323091695,7/14/2014 20:50:57,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],is rapid,N/A,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936131,7/14/2014 21:05:08,,1323098871,7/14/2014 21:04:40,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],is intermediate in,n/a,13,78,26,103,1,RO-has_manifestation,906233-FS1,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE
502936132,7/14/2014 17:13:56,,1322970130,7/14/2014 17:13:44,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],was effective for reducing,N/a,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:17:55,,1322972155,7/14/2014 17:17:42,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],effective reducing,Na,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:24:58,,1322975901,7/14/2014 17:23:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],was effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:27:44,,1322977829,7/14/2014 17:26:35,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,[TREATS],[TREATS],CLONIDINE effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:35:12,,1322984432,7/14/2014 17:34:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",was effective for reducing,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:46:58,,1322995297,7/14/2014 17:46:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATED with,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:53:39,,1322998450,7/14/2014 17:53:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],was effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 17:56:23,,1322999740,7/14/2014 17:56:15,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[PREVENTS],[PREVENTS],postmenopausal,n/a,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 18:03:46,,1323002924,7/14/2014 18:03:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],was effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 18:48:03,,1323024274,7/14/2014 18:47:45,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[TREATS],[TREATS],effective for reducing,Na,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 18:48:43,,1323024602,7/14/2014 18:48:32,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],effective for reducing,n/a,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 19:08:31,,1323036697,7/14/2014 19:08:17,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 19:21:59,,1323044496,7/14/2014 19:21:32,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],was effective,IS TREATED BY,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 20:13:25,,1323071937,7/14/2014 20:10:46,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936132,7/14/2014 21:04:38,,1323098683,7/14/2014 21:04:15,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],effective for reducing,N/A,37,0,68,9,1,RO-may_treat,907723-FS1,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
502936133,7/14/2014 17:13:11,,1322969801,7/14/2014 17:12:51,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],in,N/a,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 17:27:25,,1322977614,7/14/2014 17:26:10,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],indicating common,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 17:29:29,,1322979230,7/14/2014 17:29:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as common as,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 17:44:39,,1322994056,7/14/2014 17:44:13,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicating that,[DIAGNOSE_BY_TEST_OR_DRUG],137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 17:58:07,,1323000476,7/14/2014 17:57:49,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],nearly as common,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 18:07:08,,1323005825,7/14/2014 18:07:03,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 18:41:00,,1323020669,7/14/2014 18:40:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],CALCIFICATION in pilomatricoma.,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 18:45:13,,1323022733,7/14/2014 18:44:21,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 18:51:24,,1323026067,7/14/2014 18:50:18,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],common,none,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 19:08:17,,1323036584,7/14/2014 19:07:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],indicating,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 19:26:10,,1323046897,7/14/2014 19:24:14,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[SYMPTOM],[SYMPTOM],CALCIFICATION in pilomatricoma.,na,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 19:52:56,,1323062559,7/14/2014 19:52:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],common,n/a,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 20:08:37,,1323069708,7/14/2014 20:07:15,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[MANIFESTATION],[MANIFESTATION],as common as,N/A,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 21:06:24,,1323099475,7/14/2014 21:05:49,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],as common as in,n/a,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936133,7/14/2014 21:24:05,,1323107482,7/14/2014 21:23:31,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],nearly as common as CALCIFICATION in,n/a,137,58,149,71,1,RO-disease_may_have_finding,902676-FS1,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
502936134,7/14/2014 17:12:51,,1322969635,7/14/2014 17:12:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],"treatment,",N/a,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 17:13:28,,1322969925,7/14/2014 17:13:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"treatment,",N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 17:17:10,,1322971835,7/14/2014 17:16:54,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],crisis.,Na,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 17:30:58,,1322980481,7/14/2014 17:30:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],"treatment,",N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 17:45:26,,1322994600,7/14/2014 17:45:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],"treatment,",N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 18:07:57,,1323006137,7/14/2014 18:07:45,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 18:11:54,,1323008077,7/14/2014 18:11:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETIC KETOACIDOSIS HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,n/a,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 18:31:38,,1323016565,7/14/2014 18:30:59,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, maintenance treatment after hyperglycemic crisis.",N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 18:51:22,,1323026038,7/14/2014 18:50:08,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PREVENTS],[PREVENTS],"DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA",N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 19:04:58,,1323034834,7/14/2014 19:04:29,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],n/a,DIFFERENT TERMS,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 19:14:13,,1323039705,7/14/2014 19:13:45,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[TREATS],[TREATS],"treatment,",Na,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 20:18:28,,1323074699,7/14/2014 20:17:50,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],and,N/A,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 21:08:24,,1323100445,7/14/2014 21:07:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Diabetic ketoacidosis:,n/a,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 21:16:44,,1323104247,7/14/2014 21:16:28,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],Diabetic ketoacidosis:,n/a,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936134,7/14/2014 21:41:27,,1323117806,7/14/2014 21:40:25,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],"DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA",treats,67,34,108,55,-1,RO-cause_of,900136-FS1,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 17:20:34,,1322973368,7/14/2014 17:20:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],stressful metabolic occurrences,Na,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 17:36:42,,1322985970,7/14/2014 17:36:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 17:39:40,,1322988654,7/14/2014 17:38:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 17:52:56,,1322998141,7/14/2014 17:51:11,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 17:58:57,,1323000788,7/14/2014 17:58:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],stressful,n/a,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 18:08:59,,1323006674,7/14/2014 18:08:55,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 18:39:36,,1323020031,7/14/2014 18:38:03,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both and are brought about by numerous events.,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 18:40:07,,1323020276,7/14/2014 18:39:07,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[IS_A] [MANIFESTATION],"[MANIFESTATION]
[IS_A]","Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences",N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 18:47:33,,1323024041,7/14/2014 18:46:59,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],occurrences,none,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 18:48:30,,1323024480,7/14/2014 18:48:05,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 19:06:54,,1323035797,7/14/2014 19:06:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],DIABETIC KETOACIDOSIS (DKA) and HYPEROSMOLAR NONKETOTIC COMA (HHNC),N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 19:19:34,,1323043064,7/14/2014 19:18:46,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both and,NA,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 19:55:52,,1323064176,7/14/2014 19:55:18,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and are occurrences,n/a,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 20:27:03,,1323079061,7/14/2014 20:26:35,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],Both and,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936135,7/14/2014 20:57:22,,1323094619,7/14/2014 20:56:43,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are stressful metabolic occurrences,N/A,52,5,79,26,-1,RO-cause_of,900137-FS1,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
502936136,7/14/2014 17:15:48,,1322971123,7/14/2014 17:15:39,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],MESOTHELIOMA,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:20:15,,1322973206,7/14/2014 17:20:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],presented,Na,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:29:23,,1322979162,7/14/2014 17:28:43,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],CASE presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:36:25,,1322985685,7/14/2014 17:35:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:36:46,,1322986009,7/14/2014 17:36:11,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]",arising in a 65 year old man,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION],107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:40:48,,1322989792,7/14/2014 17:40:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],who presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:48:00,,1322995767,7/14/2014 17:47:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who presented ASCITES of unknown origin.,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 17:54:50,,1322998922,7/14/2014 17:54:28,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 18:08:17,,1323006336,7/14/2014 18:08:12,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 18:44:56,,1323022589,7/14/2014 18:44:23,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],presented,na,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 18:49:19,,1323024886,7/14/2014 18:48:48,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presented,none,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 18:57:40,,1323029910,7/14/2014 18:57:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 19:08:18,,1323036592,7/14/2014 19:07:59,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 19:14:24,,1323039844,7/14/2014 19:13:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[MANIFESTATION],[MANIFESTATION],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936136,7/14/2014 20:52:12,,1323091917,7/14/2014 20:51:43,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],presented,N/A,107,14,113,63,1,RO-disease_may_have_finding,902717-FS1,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA
502936137,7/14/2014 17:09:43,,1322967989,7/14/2014 17:09:27,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],administration of,N/a,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 17:16:54,,1322971710,7/14/2014 17:16:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],mortality,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 17:26:05,,1322976587,7/14/2014 17:25:12,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.131,[TREATS],[TREATS],administration management,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 17:43:51,,1322992757,7/14/2014 17:43:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],administration of in patients with,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 17:51:54,,1322997579,7/14/2014 17:51:29,neodev,1,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],in patients with TYPE 1 DIABETES,na,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 18:33:32,,1323017333,7/14/2014 18:32:26,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",secondary prevention of foot ulcerations healing of diabetic foot ulcers,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 18:43:34,,1323022010,7/14/2014 18:42:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],administration of in patients with,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 18:56:15,,1323028874,7/14/2014 18:55:58,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 19:07:38,,1323036238,7/14/2014 19:05:49,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],administration in patients,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 19:10:24,,1323037726,7/14/2014 19:09:59,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],administration of,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 21:08:59,,1323100682,7/14/2014 21:08:25,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],administration of,n/a,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 21:15:10,,1323103549,7/14/2014 21:13:48,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],administration in patients,N/A,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 21:18:15,,1323104876,7/14/2014 21:17:58,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],administration of,n/a,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 21:34:11,,1323112971,7/14/2014 21:32:35,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],administration,na,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936137,7/14/2014 21:34:35,,1323113184,7/14/2014 21:33:05,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],randomized clinical trial comparing INSULIN GLARGINE patients with TYPE 1 DIABETES,diagnosed by test or drug,544,510,558,526,1,RO-may_treat,907694-FS1,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE
502936138,7/14/2014 17:44:52,,1322994242,7/14/2014 17:43:54,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],better PAIN,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 17:48:45,,1322996111,7/14/2014 17:48:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],showed better,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 17:49:16,,1322996363,7/14/2014 17:48:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],comparing with,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 17:56:02,,1322999593,7/14/2014 17:55:51,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],levomepromazine,n/a,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:03:50,,1323002953,7/14/2014 18:02:44,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,One is a result of the other. None of the relation keywords seemed to explain this well.,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:04:21,,1323003168,7/14/2014 18:01:37,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:08:02,,1323006191,7/14/2014 18:07:52,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",CLOMIPRAMINE PAIN RELIEF,n/a,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:23:38,,1323013148,7/14/2014 18:23:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],CLOMIPRAMINE showed better PAIN RELIEF,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:51:20,,1323026013,7/14/2014 18:50:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[OTHER],[OTHER],1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:51:27,,1323026084,7/14/2014 18:48:43,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],showed better,n/a,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 18:53:36,,1323027227,7/14/2014 18:53:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],RELIEF,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 19:02:57,,1323033602,7/14/2014 19:02:25,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[TREATS],[TREATS],showed better,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 21:01:51,,1323097122,7/14/2014 21:01:07,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],trial with without,n/a,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 21:06:50,,1323099654,7/14/2014 21:06:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],trial comparing tramadol with,n/a,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936138,7/14/2014 21:33:14,,1323112455,7/14/2014 21:31:25,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,91,32,101,44,1,RO-may_treat,907851-FS1,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
502936139,7/14/2014 17:26:30,,1322976877,7/14/2014 17:26:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],staining in these,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 17:28:42,,1322978599,7/14/2014 17:28:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 17:37:18,,1322986515,7/14/2014 17:36:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],verified in,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 17:47:44,,1322995704,7/14/2014 17:47:02,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],as well as in these LIVER specimens.,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 17:56:18,,1322999691,7/14/2014 17:56:04,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[LOCATION],[LOCATION],in these LIVER,na,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 18:26:36,,1323014288,7/14/2014 18:23:42,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],in these LIVER specimens.,na,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 18:41:04,,1323020714,7/14/2014 18:40:41,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,none,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 18:53:11,,1323026972,7/14/2014 18:52:47,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],LIVER specimens.,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 19:24:09,,1323045703,7/14/2014 19:22:38,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[LOCATION],[LOCATION],these LIVER specimens.,Na,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 21:03:22,,1323097928,7/14/2014 21:02:14,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],staining,n/a,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 21:07:51,,1323100198,7/14/2014 21:06:24,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],in these,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 21:24:38,,1323107715,7/14/2014 21:24:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in these LIVER specimens.,n/a,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 21:36:29,,1323114294,7/14/2014 21:35:42,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],HEPATOCELLULAR NECROSIS enhanced myeloperoxidase staining in these LIVER specimens.,manifestation,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 22:00:58,,1323128588,7/14/2014 22:00:44,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[LOCATION],[LOCATION],in,N/A,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936139,7/14/2014 22:24:58,,1323143541,7/14/2014 22:23:34,clixsense,1,17548588,CAN,ON,New Hamburg,99.241.226.64,[MANIFESTATION],[MANIFESTATION],HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER,n/a,134,56,138,79,1,RO-has_finding_site,905398-FS1,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS
502936140,7/14/2014 17:13:09,,1322969799,7/14/2014 17:13:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],treatment,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 17:14:41,,1322970602,7/14/2014 17:14:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],was significantly effective in the treatment,N/a,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 17:25:49,,1322976415,7/14/2014 17:25:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 17:33:51,,1322983172,7/14/2014 17:32:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",in the treatment associated with,[ASSOCIATED_WITH] [TREATS],93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 18:02:25,,1323002283,7/14/2014 18:02:13,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],significantly effective,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 18:18:16,,1323010959,7/14/2014 18:17:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],GABAPENTIN effective in treatment of PAIN,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 18:42:56,,1323021730,7/14/2014 18:42:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS] [LOCATION],"[TREATS]
[LOCATION]",GABAPENTIN was significantly effective in treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 19:02:56,,1323033600,7/14/2014 19:02:21,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],GABAPENTIN treatment PAIN,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 19:10:06,,1323037525,7/14/2014 19:09:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 19:12:40,,1323038880,7/14/2014 19:12:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treatment of,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 19:54:21,,1323063486,7/14/2014 19:53:43,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],treatment,n/a,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 20:50:17,,1323090918,7/14/2014 20:50:05,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],effective in the treatment,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 21:09:18,,1323100820,7/14/2014 21:07:52,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],effective treatment,N/A,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 21:10:21,,1323101356,7/14/2014 21:09:39,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",pain associated,n/a,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936140,7/14/2014 21:18:23,,1323104921,7/14/2014 21:17:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],significantly effective in the treatment of pain,n/a,93,0,96,10,1,RO-may_treat,908302-FS1,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN
502936141,7/14/2014 17:15:20,,1322970858,7/14/2014 17:14:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],would be diagnosed,N/a,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 17:20:00,,1322973080,7/14/2014 17:19:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],diagnosed,Na,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 17:37:16,,1322986457,7/14/2014 17:36:48,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was predicted that,[DIAGNOSE_BY_TEST_OR_DRUG],0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 17:48:49,,1322996157,7/14/2014 17:48:23,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],BREAST CANCER INVASIVE BREAST CANCER,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 17:58:48,,1323000716,7/14/2014 17:58:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],would,n/a,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 18:04:14,,1323003120,7/14/2014 18:03:47,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],BREAST CANCER BREAST CANCER,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 18:05:38,,1323003988,7/14/2014 18:05:21,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 18:30:58,,1323016263,7/14/2014 18:30:03,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],BREAST CANCER,n/a,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 18:37:19,,1323018953,7/14/2014 18:36:40,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; situ disease would be diagnosed in 62,030 women;",N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 18:59:15,,1323031015,7/14/2014 18:57:57,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],BREAST CANCER was INVASIVE BREAST CANCER,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 19:01:48,,1323032832,7/14/2014 19:01:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],BREAST CANCER INVASIVE BREAST CANCER,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 19:07:23,,1323036047,7/14/2014 19:07:02,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[IS_A],[IS_A],would be diagnosed,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 19:24:46,,1323046052,7/14/2014 19:24:16,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[IS_A],[IS_A],was,Na,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 20:27:25,,1323079199,7/14/2014 20:27:04,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],diagnosed in,N/A,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936141,7/14/2014 21:15:07,,1323103516,7/14/2014 21:13:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],INVASIVE BREAST CANCER,n/a,0,67,12,89,1,RO-disease_has_primary_anatomic_site,902286-FS1,"BREAST CANCER  It was predicted that in the United States in 2007, INVASIVE BREAST CANCER would be diagnosed in an estimated 178,480 women; in situ disease would be diagnosed in 62,030 women; and 40,460 women would die of the disease.",BREAST CANCER,INVASIVE BREAST CANCER
502936142,7/14/2014 17:15:19,,1322970850,7/14/2014 17:15:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],9 year,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:15:35,,1322970990,7/14/2014 17:15:21,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],implantation of an,N/a,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:18:34,,1322972422,7/14/2014 17:18:10,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],experience implantation,Na,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:23:55,,1322975193,7/14/2014 17:23:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:44:32,,1322993924,7/14/2014 17:43:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in a 9 year old girl with,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:56:34,,1322999800,7/14/2014 17:56:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],year,n/a,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 17:57:25,,1323000144,7/14/2014 17:57:09,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],implantation,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 18:06:28,,1323005455,7/14/2014 18:05:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],implantation of an,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 18:32:32,,1323016990,7/14/2014 18:31:46,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],N/A,"The girl already had the condition before the implantation, so the two are not necessarily linked.",50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 18:46:18,,1323023311,7/14/2014 18:46:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],with implantation of an,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 18:55:57,,1323028678,7/14/2014 18:55:11,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],implantation,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 18:58:50,,1323030727,7/14/2014 18:56:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],implantation of,n/a,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 19:07:00,,1323035847,7/14/2014 19:06:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[TREATS],[TREATS],implantation of,N/A,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 19:08:13,,1323036544,7/14/2014 19:06:54,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936142,7/14/2014 19:24:13,,1323045749,7/14/2014 19:22:32,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],implantation,na,50,97,69,144,-1,RO-has_manifestation,906368-FS1,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA
502936143,7/14/2014 17:18:37,,1322972438,7/14/2014 17:18:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],resulting in,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 17:19:02,,1322972609,7/14/2014 17:18:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],resulting,Na,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 17:24:08,,1322975331,7/14/2014 17:23:22,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[MANIFESTATION],[MANIFESTATION],concentrations resulting,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 17:42:14,,1322991195,7/14/2014 17:41:42,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",resulting in,[CAUSES] [SIDE_EFFECT],334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 17:43:30,,1322992398,7/14/2014 17:43:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],resulting in,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 17:55:12,,1322999094,7/14/2014 17:54:52,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resulting,n/a,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 18:05:57,,1323004371,7/14/2014 18:05:45,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 18:15:33,,1323009794,7/14/2014 18:15:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],(increased ERGOT ALKALOIDS resulting in ERGOTISM),N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 18:21:39,,1323012381,7/14/2014 18:20:05,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],resulting,na,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 18:40:50,,1323020582,7/14/2014 18:40:08,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[SIDE_EFFECT],[SIDE_EFFECT],Digoxin Increased digoxin plasma concentrations,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 19:12:19,,1323038682,7/14/2014 19:11:56,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],resulting in,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 20:59:35,,1323095977,7/14/2014 20:58:24,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],"If used concomitantly,",N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 21:06:24,,1323099469,7/14/2014 21:05:17,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],resulting in,N/A,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 21:11:22,,1323101810,7/14/2014 21:10:50,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],resulting in ERGOTISM),n/a,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936143,7/14/2014 21:16:09,,1323103992,7/14/2014 21:15:45,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],resulting,n/a,334,363,348,371,1,RO-has_causative_agent,903773-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM
502936144,7/14/2014 17:14:14,,1322970362,7/14/2014 17:13:57,instagc,1.0,18960682,GBR,"","",86.29.147.112,[IS_A],[IS_A],is the clinical term,N/a,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:15:38,,1322971037,7/14/2014 17:15:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PNEUMONIA,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:27:15,,1322977494,7/14/2014 17:27:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],is the clinical term,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:30:46,,1322980359,7/14/2014 17:29:14,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],is the clinical term for,na,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:31:42,,1322981162,7/14/2014 17:31:21,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],clinical term for,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:42:50,,1322991787,7/14/2014 17:42:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is for,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:44:19,,1322993514,7/14/2014 17:43:53,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:48:20,,1322995894,7/14/2014 17:48:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],is the clinical term for,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:54:12,,1322998650,7/14/2014 17:54:02,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"heterogeneity,",n/a,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 17:59:35,,1323001029,7/14/2014 17:59:12,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[IS_A],[IS_A],is the clinical term,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 18:26:37,,1323014311,7/14/2014 18:26:03,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],is the clinical term for,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 18:36:35,,1323018666,7/14/2014 18:36:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],is the clinical term for,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 18:42:21,,1323021431,7/14/2014 18:41:34,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[IS_A],[IS_A],IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 19:03:50,,1323034108,7/14/2014 19:03:17,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[IS_A],[IS_A],is the clinical term,N/A,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936144,7/14/2014 19:17:24,,1323041567,7/14/2014 19:14:54,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[IS_A],[IS_A],clinical term for,Na,55,0,82,29,-1,RO-has_manifestation,906127-FS1,"IDIOPATHIC PULMONARY FIBROSIS is the clinical term for USUAL INTERSTITIAL PNEUMONIA the characteristic histologic pattern is interstitial fibrosis with temporal heterogeneity, and the radiologic pattern is basal and subpleural areas of ground glass and reticular attenuation and honeycomb pattern.",USUAL INTERSTITIAL PNEUMONIA,IDIOPATHIC PULMONARY FIBROSIS
502936145,7/14/2014 17:12:22,,1322969434,7/14/2014 17:11:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in a,N/a,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:14:55,,1322970685,7/14/2014 17:14:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],GLUTEN FREE,Na,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:17:07,,1322971807,7/14/2014 17:16:55,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DISEASE,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:19:04,,1322972619,7/14/2014 17:18:39,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:25:08,,1322976022,7/14/2014 17:24:12,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[PREVENTS],[PREVENTS],DIET.,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:43:52,,1322992781,7/14/2014 17:42:30,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],toxic to individuals with CELIAC DISEASE and were not allowed,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:46:33,,1322995148,7/14/2014 17:45:57,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were not allowed in,[DIAGNOSE_BY_TEST_OR_DRUG],107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:53:22,,1322998330,7/14/2014 17:52:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],DIET.,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 17:54:33,,1322998816,7/14/2014 17:54:13,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[TREATS],[TREATS],allowed in a GLUTEN FREE DIET.,na,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 18:07:14,,1323005848,7/14/2014 18:07:09,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 18:49:27,,1323024981,7/14/2014 18:48:32,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[CAUSES],[CAUSES],were considered to be toxic,Na,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 18:56:17,,1323028882,7/14/2014 18:54:49,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not allowed in,n/a,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 19:11:35,,1323038322,7/14/2014 19:11:12,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PREVENTS],[PREVENTS],were not allowed,N/A,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 19:53:42,,1323063253,7/14/2014 19:52:58,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],considered,n/a,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936145,7/14/2014 21:08:51,,1323100634,7/14/2014 21:08:34,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],were not allowed,n/a,107,66,122,80,-1,RO-has_causative_agent,903777-FS1,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE
502936146,7/14/2014 17:19:47,,1322972956,7/14/2014 17:19:31,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],presented moderate,Na,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 17:29:03,,1322978845,7/14/2014 17:28:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],features,N/A,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 17:47:03,,1322995351,7/14/2014 17:46:35,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",with diagnostic features of,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 17:55:10,,1322999085,7/14/2014 17:54:34,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[CAUSES],[CAUSES],diagnostic features of ADENOCARCINOMA OF THE OVARY,na,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 17:58:08,,1323000507,7/14/2014 17:57:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],diagnostic,n/a,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:06:30,,1323005463,7/14/2014 18:06:21,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASCITES ADENOCARCINOMA OF THE OVARY,n/a,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:21:49,,1323012474,7/14/2014 18:21:29,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[MANIFESTATION],[MANIFESTATION],ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,N/A,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:32:58,,1323017129,7/14/2014 18:32:32,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with diagnostic features of,N/A,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:34:31,,1323017792,7/14/2014 18:34:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],with diagnostic features of,N/A,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:35:19,,1323018146,7/14/2014 18:32:28,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],with diagnostic features of,n/a,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 18:45:50,,1323023088,7/14/2014 18:45:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],presented,na,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 19:00:17,,1323031839,7/14/2014 18:59:46,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,separate terms,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 19:24:06,,1323045653,7/14/2014 19:23:37,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],diagnostic features,NA,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 19:59:17,,1323065714,7/14/2014 19:58:25,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],diagnostic,n/a,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936146,7/14/2014 20:23:55,,1323077447,7/14/2014 20:23:39,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],diagnostic features of,N/A,44,80,50,107,1,RO-disease_may_have_finding,902568-FS1,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY
502936147,7/14/2014 17:15:58,,1322971202,7/14/2014 17:15:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],rarely noticed COMPLICATION,N/a,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 17:37:37,,1322986773,7/14/2014 17:36:45,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[SYMPTOM],[SYMPTOM],is a rarely noticed COMPLICATION PREGNANCY,na,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 17:43:31,,1322992419,7/14/2014 17:42:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],is noticed,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 17:48:21,,1322995904,7/14/2014 17:47:44,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",is a rarely noticed,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 17:49:09,,1322996314,7/14/2014 17:48:49,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[SYMPTOM],[SYMPTOM],noticed,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 17:49:50,,1322996581,7/14/2014 17:48:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],eclampsia without the classical a rarely noticed COMPLICATION,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 18:07:51,,1323006113,7/14/2014 18:06:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA COMPLICATION OF PREGNANCY,n/a,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 18:39:49,,1323020119,7/14/2014 18:39:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],is a rarely noticed,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 18:45:44,,1323023033,7/14/2014 18:44:59,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA is COMPLICATION OF PREGNANCY,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 19:06:18,,1323035516,7/14/2014 19:05:58,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],rarely noticed COMPLICATION,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 19:06:50,,1323035768,7/14/2014 19:06:02,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],is,none,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 19:11:08,,1323038135,7/14/2014 19:10:34,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],rarely noticed COMPLICATION,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 19:52:22,,1323062358,7/14/2014 19:50:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CONTRAINDICATES],[CONTRAINDICATES],rarely noticed,na,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 19:55:17,,1323063956,7/14/2014 19:54:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],COMPLICATION,n/a,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936147,7/14/2014 20:26:34,,1323078760,7/14/2014 20:26:13,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],is a,N/A,124,48,148,86,-1,RO-disease_has_finding,901512-FS1,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
502936148,7/14/2014 17:11:23,,1322968837,7/14/2014 17:10:55,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],"number of headaches,",N/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 17:33:11,,1322982504,7/14/2014 17:32:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 17:54:24,,1322998748,7/14/2014 17:54:14,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[LOCATION],[LOCATION],number,n/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:05:11,,1323003843,7/14/2014 18:04:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],causes such as,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:14:06,,1323009112,7/14/2014 18:13:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:19:30,,1323011465,7/14/2014 18:18:55,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:32:25,,1323016938,7/14/2014 18:31:39,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[CAUSES],[CAUSES],"secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:41:11,,1323020784,7/14/2014 18:40:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ANGINAL,n/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 18:54:00,,1323027394,7/14/2014 18:53:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[MANIFESTATION],[MANIFESTATION],PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 20:10:05,,1323070347,7/14/2014 20:09:38,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 21:07:40,,1323100109,7/14/2014 21:06:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],secondary causes such as,n/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 21:09:36,,1323100964,7/14/2014 21:09:09,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE,n/a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 21:27:13,,1323109104,7/14/2014 21:25:11,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[NONE],[NONE],N/A,The words are all part of the same term,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 21:30:50,,1323111185,7/14/2014 21:29:56,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE,is a,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936148,7/14/2014 22:00:43,,1323128465,7/14/2014 22:00:11,neodev,1.0,21405167,USA,MD,Glen Burnie,69.137.237.73,[OTHER],[OTHER],such as PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE,N/A,157,140,190,156,-1,RO-disease_may_have_finding,902844-FS1,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA
502936149,7/14/2014 17:12:51,,1322969636,7/14/2014 17:12:43,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],common,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 17:14:29,,1322970479,7/14/2014 17:14:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"In this species,",N/a,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 17:40:10,,1322989175,7/14/2014 17:39:12,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]",intermittent,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 18:02:08,,1323002177,7/14/2014 18:01:16,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are all known to share,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 18:15:11,,1323009583,7/14/2014 18:14:37,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES LIGHT STIMULATION INDUCED SEIZURES are all known share common electroclinical phenomenology.,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 18:36:39,,1323018676,7/14/2014 18:36:05,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 19:01:33,,1323032652,7/14/2014 19:01:02,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],share,none,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 19:04:03,,1323034236,7/14/2014 19:03:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different kinds of seizures,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 19:04:10,,1323034314,7/14/2014 19:02:57,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES LIGHT STIMULATION INDUCED SEIZURES are all known,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 20:53:47,,1323092757,7/14/2014 20:53:17,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],all known to share,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 21:25:13,,1323107991,7/14/2014 21:24:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],all known share,n/a,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 21:29:21,,1323110359,7/14/2014 21:27:53,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],share common,N/A,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 21:38:27,,1323115507,7/14/2014 21:38:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],intermittent,n/a,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 21:42:11,,1323118346,7/14/2014 21:41:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES,is a,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936149,7/14/2014 21:44:28,,1323120190,7/14/2014 21:43:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[OTHER],[OTHER],common electroclinical phenomenology.,na,74,17,107,60,-1,RO-has_definitional_manifestation,904592-FS1,"In this species, SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES intermittent LIGHT STIMULATION INDUCED SEIZURES and kindled generalized convulsive seizures are all known to share a common electroclinical phenomenology.",LIGHT STIMULATION INDUCED SEIZURES,SPONTANEOUS GENERALIZED CONVULSIVE SEIZURES
502936150,7/14/2014 17:16:12,,1322971368,7/14/2014 17:16:00,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],treatment of,N/a,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 17:16:32,,1322971559,7/14/2014 17:16:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],treatment,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 17:21:41,,1322973903,7/14/2014 17:20:54,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CONTRAINDICATES],[CONTRAINDICATES],Should not be used,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 17:39:10,,1322988218,7/14/2014 17:38:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],Related to Treatment,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 17:46:53,,1322995286,7/14/2014 17:46:26,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[OTHER],[OTHER],given in conjunction ANTITUBERCULOSIS,na,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 17:52:37,,1322997959,7/14/2014 17:51:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],must be given,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:02:12,,1323002202,7/14/2014 18:01:48,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[TREATS],[TREATS],ANTITUBERCULOSIS,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:04:39,,1323003309,7/14/2014 18:04:22,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:34:51,,1323017915,7/14/2014 18:34:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,[TREATS],[TREATS],Treatment of Tuberculosis treatment of TB; ANTITUBERCULOSIS agents.,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:38:53,,1323019689,7/14/2014 18:38:16,prodege,1.0,9378607,GBR,H9,London,90.201.89.10,[TREATS],[TREATS],treatment of TB; in conjunction with other ANTITUBERCULOSIS agents.,n/a,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:44:41,,1323022473,7/14/2014 18:44:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],must be given in conjunction with other ANTITUBERCULOSIS agents.,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:52:19,,1323026605,7/14/2014 18:51:19,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment ANTITUBERCULOSIS,N/A,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 18:53:57,,1323027386,7/14/2014 18:53:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],Treatment of,n/a,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 19:50:35,,1323061570,7/14/2014 19:50:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],conjunction,n/a,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936150,7/14/2014 21:05:48,,1323099155,7/14/2014 21:05:09,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],other,n/a,97,141,98,157,1,RO-may_treat,907860-FS1,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS
502936151,7/14/2014 17:16:25,,1322971522,7/14/2014 17:16:12,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],contribute,Na,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 17:28:02,,1322978004,7/14/2014 17:27:29,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[SYMPTOM],[SYMPTOM],contribute,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 17:36:04,,1322985339,7/14/2014 17:35:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 17:38:25,,1322987538,7/14/2014 17:37:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 17:59:53,,1323001151,7/14/2014 17:59:36,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],may contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:01:15,,1323001811,7/14/2014 18:00:32,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],and thus may contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:13:18,,1323008739,7/14/2014 18:13:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",ELEVATED BLOOD PRESSURE THE ACCELERATION OF HYPERTENSION,n/a,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:23:40,,1323013154,7/14/2014 18:21:40,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],contribute,na,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:24:34,,1323013463,7/14/2014 18:23:59,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],presence of extensive renal arteriolar ELEVATED BLOOD PRESSURE may contribute to THE ACCELERATION OF HYPERTENSION,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:29:05,,1323015464,7/14/2014 18:28:11,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and thus may contribute to,N/a,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:36:35,,1323018664,7/14/2014 18:35:52,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],may contribute to,n/a,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:45:41,,1323023018,7/14/2014 18:45:00,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may contribute to,Na,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 18:47:00,,1323023683,7/14/2014 18:45:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[PART_OF] [CAUSES],"[CAUSES]
[PART_OF]",ELEVATED BLOOD PRESSURE may contribute THE ACCELERATION OF HYPERTENSION,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 19:00:37,,1323032074,7/14/2014 19:00:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936151,7/14/2014 20:50:04,,1323090827,7/14/2014 20:49:40,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],contribute to,N/A,165,216,187,248,-1,RO-has_definitional_manifestation,904990-FS1,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
502936152,7/14/2014 17:14:29,,1322970495,7/14/2014 17:14:22,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],specifically,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:21:01,,1322973566,7/14/2014 17:20:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],genome,Na,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:21:10,,1322973635,7/14/2014 17:19:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[CAUSES],[CAUSES],amplified,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:32:49,,1322982160,7/14/2014 17:32:12,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],amplified specifically a 434 bp DNA fragment from,[DIAGNOSE_BY_TEST_OR_DRUG],58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:37:59,,1322987174,7/14/2014 17:37:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],genome,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:43:10,,1322992100,7/14/2014 17:42:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:54:11,,1322998627,7/14/2014 17:52:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",amplified,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 17:55:38,,1322999411,7/14/2014 17:55:30,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,[MANIFESTATION],[MANIFESTATION],epidemic,n/a,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 18:13:37,,1323008849,7/14/2014 18:13:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],sequence of RICKETTSIA RICKETTSII from genome of ROCKY MOUNTAIN SPOTTED FEVER,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 18:30:15,,1323015977,7/14/2014 18:29:05,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],a 434 bp DNA fragment from the genome of,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 18:48:30,,1323024481,7/14/2014 18:47:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],amplified genome,n/a,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 18:56:49,,1323029247,7/14/2014 18:56:24,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[ASSOCIATED_WITH],[ASSOCIATED_WITH],specifically a,Na,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 19:00:09,,1323031714,7/14/2014 18:59:16,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],RICKETTSIA RICKETTSII amplified ROCKY MOUNTAIN SPOTTED FEVER,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 19:00:38,,1323032072,7/14/2014 19:00:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],amplified from genome of,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936152,7/14/2014 19:01:26,,1323032629,7/14/2014 19:01:02,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],amplified specifically genome,N/A,58,144,78,172,1,RO-has_causative_agent,903784-FS1,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER
502936153,7/14/2014 17:09:05,,1322967622,7/14/2014 17:08:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],is a major,N/a,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 17:14:34,,1322970535,7/14/2014 17:14:21,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],major,Na,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 17:19:45,,1322972929,7/14/2014 17:19:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[IS_A],[IS_A],is a,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 17:50:33,,1322996917,7/14/2014 17:49:52,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[IS_A],[IS_A],is a major,na,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 17:59:11,,1323000908,7/14/2014 17:58:29,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],major COMPLICATION,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:05:54,,1323004166,7/14/2014 18:05:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],is a,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:08:34,,1323006485,7/14/2014 18:08:30,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,[NONE],[NONE],na,na,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:10:47,,1323007599,7/14/2014 18:09:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",PREECLAMPSIA COMPLICATION OF PREGNANCY,n/a,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:31:45,,1323016691,7/14/2014 18:31:25,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],is a major OF,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:34:48,,1323017894,7/14/2014 18:34:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],is a major,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:52:51,,1323026850,7/14/2014 18:52:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],a major,n/a,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 18:54:07,,1323027500,7/14/2014 18:51:39,clixsense,1.0,15189335,GBR,C7,Coventry,94.197.120.183,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is major,Na,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 19:01:40,,1323032752,7/14/2014 19:01:27,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],is a,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 19:06:06,,1323035427,7/14/2014 19:05:36,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],PREECLAMPSIA is a COMPLICATION OF PREGNANCY,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936153,7/14/2014 19:10:49,,1323037966,7/14/2014 19:10:26,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],is a major,N/A,24,0,48,12,-1,RO-disease_has_finding,901762-FS1,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
502936154,7/14/2014 17:30:29,,1322980099,7/14/2014 17:29:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,[IS_A],[IS_A],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 17:42:08,,1322991075,7/14/2014 17:41:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",including association with,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 17:46:10,,1322994942,7/14/2014 17:45:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 17:48:48,,1322996121,7/14/2014 17:48:17,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,[CAUSES],[CAUSES],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 18:00:40,,1323001563,7/14/2014 18:00:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 18:08:16,,1323006327,7/14/2014 18:07:42,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 18:28:10,,1323015083,7/14/2014 18:27:53,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 18:45:05,,1323022667,7/14/2014 18:44:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 19:19:58,,1323043253,7/14/2014 19:18:55,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,Na,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 19:48:49,,1323060449,7/14/2014 19:46:18,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[IS_A],[IS_A],including,na,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 19:49:34,,1323060906,7/14/2014 19:49:16,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",including association,n/a,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 20:23:11,,1323077056,7/14/2014 20:20:55,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 20:33:46,,1323082588,7/14/2014 20:32:37,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,[IS_A],[IS_A],including,na,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 20:50:40,,1323091132,7/14/2014 20:50:18,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],in association with,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936154,7/14/2014 21:05:17,,1323098918,7/14/2014 21:02:49,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],including,N/A,22,42,30,50,-1,RO-has_definitional_manifestation,904754-FS1,Many women experience HEADACHES including MIGRAINE in association with their menstrual cycles.,HEADACHES,MIGRAINE
502936155,7/14/2014 17:12:34,,1322969531,7/14/2014 17:12:23,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],including,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 17:27:29,,1322977658,7/14/2014 17:27:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[MANIFESTATION],[MANIFESTATION],manifestations,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 17:31:48,,1322981266,7/14/2014 17:31:28,neodev,1.0,18963376,GBR,A5,Bedford,92.6.230.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES including other manifestations of DIABETIC NEUROPATHY,na,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 17:41:07,,1322990148,7/14/2014 17:40:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],including of,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 17:48:23,,1322995934,7/14/2014 17:47:45,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[MANIFESTATION],[MANIFESTATION],manifestations,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 18:00:19,,1323001363,7/14/2014 17:59:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],other manifestations of,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 18:27:52,,1323014926,7/14/2014 18:27:16,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],including other manifestations of,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 18:53:29,,1323027148,7/14/2014 18:52:52,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],manifestations,n/a,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 19:06:41,,1323035670,7/14/2014 19:06:19,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],manifestations,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 19:09:06,,1323037054,7/14/2014 19:08:39,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],DIABETES manifestations DIABETIC NEUROPATHY,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 19:50:12,,1323061343,7/14/2014 19:49:55,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],manifestations,n/a,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 20:29:44,,1323080587,7/14/2014 20:28:50,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],manifestations of,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 21:17:34,,1323104587,7/14/2014 21:17:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],manifestations,n/a,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 21:35:01,,1323113418,7/14/2014 21:33:15,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],manifestations of,N/A,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
502936155,7/14/2014 21:40:25,,1323116922,7/14/2014 21:39:39,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],"history DIABETES of long duration, manifestations DIABETIC NEUROPATHY",manifestation,105,44,123,52,-1,RO-cause_of,900157-FS1,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
